Full title:

LAMP-coupled CRISPR-Cas12a assays for upgrading molecular

detection of *Leishmania* infections

Short title:

LAMP-CRISPR mediated *Leishmania* detection

Eva Dueñas[1,#a¶], Ingrid Tirado[1,2¶], Percy Huaihua[3], Ariana Parra del Riego[1], Luis

Cabrera-Sosa[1,4,#b], Jose A. Nakamoto[1,#c], María Cruz[5], Carlos M. Restrepo[6], Jorge

Arévalo[3,4], Vanessa Adaui[1,4*]

[1] Laboratory of Biomolecules, Faculty of Health Sciences, Universidad Peruana de

Ciencias Aplicadas (UPC), Lima, Peru; [2] Facultad de Ciencias Biológicas, Universidad

Nacional Mayor de San Marcos, Lima, Peru; [3] Laboratorio de Patho-antígenos,

Laboratorios de Investigación y Desarrollo, Facultad de Ciencias e Ingeniería,

Universidad Peruana Cayetano Heredia, Lima, Peru; [4] Instituto de Medicina Tropical

Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru; [5]

Facultad de Ciencias de la Salud, Universidad Andina del Cusco, Cusco, Peru; [6] Centro

de Biología Molecular y Celular de Enfermedades, Instituto de Investigaciones

Científicas y Servicios de Alta Tecnología (INDICASAT AIP), Panama City, Panama

[#a]Current Address: Life Science Research Centre, Faculty of Science, University of

Ostrava, Ostrava, Czech Republic

[#b]Current Address: Department of Biomedical Sciences, Institute of Tropical Medicine

Antwerp, Antwerp, Belgium

#cCurrent Address: Laboratory of Protein Evolution, Department of Experimental

Medical Science, Lund University, Lund, Sweden

*Corresponding author: vanessa.adaui@upc.pe (VA)

¶These authors contributed equally to this work.

Keywords: leishmaniasis, *Leishmania*, CRISPR-Cas, nucleic acid detection, isothermal

amplification, LAMP, kDNA, 18S rDNA

Abstract

Background: Tegumentary leishmaniasis is a parasitic disease endemic in the Americas. Its clinical management and control rely on early and accurate diagnosis and adequate treatment. PCR-based molecular diagnostics offer high sensitivity and specificity over microscopy or culture but are less accessible in low-resource settings. New molecular tools for detecting *Leishmania* infections are needed in rural endemic regions. A promising tool harnessing CRISPR-Cas technology enables highly specific and sensitive detection of nucleic acid targets, offering an exciting potential for portable molecular diagnostics. Previously, we developed CRISPR-Cas12a-based assays coupled to PCR preamplification for *Leishmania* detection. Here, we adapted our assays, which target the 18S rDNA and kinetoplast DNA (kDNA) minicircles, by replacing PCR with loop-mediated isothermal amplification (LAMP).

Methodology/Principal Findings: LAMP-CRISPR assays were optimized for fluorescence-based and lateral flow readouts. The assays could detect as low as 0.2 genome equivalents per reaction using *L. braziliensis* M2904 strain genomic DNA. The kDNA assay reliably detected all tested species of the *Leishmania* (*Viannia*) subgenus, while the 18S assay showed pan-*Leishmania* detection capability. There was no cross-reactivity with other protozoan (*Trypanosoma cruzi* and *Plasmodium falciparum*) and bacterial (*Mycobacterium tuberculosis*) pathogen DNA, or with human DNA. When applied to 90 clinical samples (skin lesions) from the Cusco region of Peru and compared to kDNA real-time PCR, LAMP-CRISPR assays with a fluorescence readout achieved a sensitivity of 90.9% for kDNA and 72.7% for 18S rDNA, both with 100% specificity. Overall, lateral flow strip results agreed with fluorescence-based detection in 18 tested samples, with one discrepancy observed in the 18S assay associated with low parasite load.

Conclusions/Significance: These new assays, being amenable to further simplification and optimization for their adoption in low-resource settings, hold promise as a new generation of accurate molecular tools for leishmaniasis diagnosis and surveillance, supporting One Health strategies for disease control.

Author Summary

Tegumentary leishmaniasis affects poverty-related populations in the Americas and encompasses skin and mucosal lesions that can cause disfigurement and social stigma. The disease is caused by several species of the protozoan parasite *Leishmania*. PCR-based molecular diagnostics are currently the most sensitive and specific diagnostic tools. Yet, these require specialized infrastructure and trained personnel that are not readily available in low-resource settings. New tools are required to meet the diagnostic needs in rural endemic areas. A promising tool leveraging CRISPR-Cas technology enables cost-effective, *in vitro* nucleic acid detection, paving the way for diagnostic solutions that could be made available to patients at, or near, the point of care. Here, we harnessed the CRISPR-Cas12a system combined with loop-mediated isothermal amplification (LAMP) to develop assays capable of detecting multiple *Leishmania* species of medical importance. Our assays employ multi-copy targets widely used in molecular diagnostics: the 18S rDNA for pan-*Leishmania* detection and a kDNA minicircle region conserved among *L*. (*Viannia*) species. Results can be read with either fluorescence detection or lateral flow strips. Both assays showed satisfying performance in both analytical validation and clinical sample testing under laboratory conditions. These new tools show promise to improve diagnosis and surveillance of leishmaniasis.

Introduction

Leishmaniasis is one of the most serious neglected infectious diseases, with 0.7 to 1 million new cases each year and between 20,000 and 30,000 deaths [1, 2]. As a vector-borne disease, leishmaniasis poses a substantial threat to millions of individuals in regions where the disease is endemic, which include Asia, South and Central America, Africa and the Mediterranean basin [3]. Leishmaniasis results from an infection with protozoan parasites of the genus *Leishmania* that are transmitted to humans (and other mammals) through the bite of infected sandflies and manifests in two main clinical forms: cutaneous (or tegumentary) and visceral leishmaniasis, each presenting unique challenges in terms of diagnosis, treatment, and control [4, 5]. In the Americas, tegumentary leishmaniasis is widely distributed in 18 endemic countries and comprises a spectrum of clinical conditions ranging from localized skin ulcers to severe disfiguring mucosal lesions [5]. This clinical pleomorphism is largely dependent on the immune responses of the human host as well as on factors intrinsic to the different infecting *Leishmania* species [6]. Diverse *Leishmania* species from the *Viannia* and *Leishmania* subgenera circulate in several Central and South American countries, with the former being responsible for the majority of leishmaniasis cases [4]. While efforts directed toward the development of effective prophylactic and therapeutic vaccines against human leishmaniasis are ongoing, early and accurate diagnosis paired with timely chemotherapy remain the most vital tools in the fight against the leishmaniases [7].

The diagnostic tools currently available for the detection of *Leishmania* spp. infections include direct smear examination (light microscopy), *in vitro* culture, immunological and molecular techniques [8]. Among the nucleic acid amplification techniques (NAATs), the polymerase chain reaction (PCR) and its variants, such as real-time PCR, currently provide the most sensitive and specific diagnostic tools available,

and several assays have been developed for the detection and identification of *Leishmania*

species [9, 10]. While accessible in research and reference laboratories, PCR-based

methods may not be readily available in rural endemic areas since they require

infrastructure, resources, and technical expertise [11]. Because of this, (near) point-of-

care (PoC) diagnostic tests have become a noteworthy concept, as they would allow

easier, faster and less expensive diagnostic alternatives that need only minimal laboratory

setup [12]. Advancements towards simplifying molecular diagnostic tools gave rise to

multiple isothermal NAATs, such as loop-mediated isothermal amplification (LAMP)

and recombinase polymerase amplification (RPA), which hold potential to decentralize

molecular diagnostic testing [13]. Of these, LAMP has gained prominence due to its

simplicity and effectiveness in detecting nucleic acid sequences with high specificity.

LAMP is different from the traditional PCR as it operates at a constant temperature (60-

65°C), eliminating the need for complex thermal cycling equipment [14, 15]. The LAMP

reaction uses 4 to 6 primers that target specific DNA sequences, along with the Bst DNA

polymerase, an enzyme that displays a strong strand displacement activity [14]. LAMP

amplifies the target DNA producing a concatenated DNA product with stem-loop DNA

structures, yielding up to 10^9 copies in less than an hour [14]. The results can be easily

visualized, e.g. on the basis of the turbidity caused by reaction by-products [16], or with

the use of sequence-specific probes [17, 18]. Due to its user-friendly nature and rapidity,

LAMP holds great promise as a tool for the diagnosis of infectious diseases in resource-

limited settings [19]. Several studies have reported LAMP assays for genus-, complex-

or species-specific detection of *Leishmania*; these achieved high sensitivity and

specificity and showed good diagnostic performance for human cutaneous leishmaniasis

(CL) and visceral leishmaniasis (VL) (reviewed in [20, 21]). A commercially available

LAMP kit (Loopamp™ *Leishmania* Detection Kit, developed by Eiken Chemical, Japan)

to detect *Leishmania* DNA has also been evaluated for the diagnosis of human CL and

VL and showed comparable performance to PCR-based methods [22].

Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-

associated proteins (Cas) technology has recently been harnessed as a tool for molecular

detection and the development of CRISPR-based diagnostics [23], based on the discovery

that once Cas12a and Cas13a enzymes bound to CRISPR RNA (crRNA) recognize

specific nucleic acid targets, they become activated, thereby catalyzing cleavage of both

the targets (*cis*-cleavage) as well as non-target nucleic acids (*trans*-cleavage) [24, 25].

This collateral *trans*-cleavage activity can be applied for nucleic acid detection by

coupling it with a reporter molecule. For fluorescence-based assays, the reporter molecule

consists of a DNA or RNA oligomer carrying a fluorophore and a quencher. So, upon

target recognition, reporter cleavage by the activated Cas enzyme generates a detectable

fluorescence signal that indicates that the target nucleic acid sequence is present in a

sample. Alternatively, visualization of the Cas detection reaction can be achieved by a

lateral flow strip readout using a reporter molecule labeled with FAM or digoxin and

biotin [26, 27]. CRISPR-based assay platforms reported thus far enable a highly sensitive

detection of nucleic acids in the attomolar range when combined with a target

preamplification step using either isothermal NAATs (e.g. DETECTR [24] and

SHERLOCK [25]) or PCR-based NAATs (e.g. HOLMES [28]). Notwithstanding that this

two-step CRISPR-based assay format increases assay complexity and poses the risk of

cross-contamination during sample transfer to the CRISPR reaction, it is a convenient

way to pursue in the first development phase of CRISPR-based assays to demonstrate

their potential for further assay development [29]. More recent efforts aim for

amplification-free detection of nucleic acid targets with CRISPR, and the proof-of-

concept was demonstrated for direct detection of pathogen RNA and DNA with

quantitative ability [30-33].

The combination of CRISPR-Cas and LAMP technologies has advanced the

progress of nucleic acid-based PoC diagnostic test development. Coupling LAMP

reactions to downstream CRISPR-based detection improves specificity [19, 23], since

LAMP is prone to non-specific amplification [34]. Integrated LAMP-CRISPR assays

have been developed for the detection of several pathogens, including viruses (e.g. SARS-

CoV-2 [26, 35-37], human papillomavirus [38]), bacteria (e.g. *Mycobacterium*

tuberculosis [39], *Klebsiella pneumoniae* [40]), and fungi (e.g. *Verticillium dahliae* [41]).

CRISPR-based assays have also been developed for the detection of parasites of medical

and veterinary importance, such as the protozoa *Plasmodium* spp. [29, 42], *Toxoplasma*

gondii [43], *Leishmania* spp. [44-47], *Trypanosoma brucei* [48, 49], and *Trypanosoma*

cruzi [50]; and the trematode *Schistosoma* species [51, 52]. These assays, aiming at

sensing parasite nucleic acid sequences in biological specimens, mostly combined

CRISPR with RPA preamplification. Applications of LAMP-CRISPR for parasite

detection are increasing, as illustrated by the detection of *Schistosoma* infection in host

samples [53], the *in silico* design of LAMP primers and Cas12a crRNA sequences for

identifying genetic polymorphisms associated with drug resistance in *P. falciparum*

infections [54], the detection of *T. gondii* in environmental samples [55], and the detection

of *T. cruzi* in infants for diagnosing acute congenital infection [56].

At present, leishmaniasis diagnosis in endemic areas is impaired mainly by the

lack of infrastructure, equipment, trained human resources, and low access (if any) to

effective diagnostic tools. New molecular diagnostic tools that are accurate, easy to use,

accessible and affordable for use in resource-limited settings are required. In previous

work, we developed CRISPR-Cas12a-based assays coupled to PCR preamplification for

detection of *Leishmania* spp. in clinical samples [45]. Here, we have adapted our assays,

which target the *Leishmania* 18S ribosomal RNA gene (18S rDNA) and minicircle

kinetoplast DNA (kDNA), by replacing PCR with LAMP in the preamplification step, to

facilitate the road towards the development of a nucleic acid-based near-PoC diagnostic

tool for leishmaniasis. We optimized LAMP-CRISPR assay conditions with a

fluorescence signal readout in a plate reader as well as a visual readout on lateral flow

strips. We report the evaluation of LAMP-CRISPR assay diagnostic performance against

a kDNA real-time PCR assay on stored clinical samples from the Cusco region, a highly

endemic area for tegumentary leishmaniasis in south-central Peru where *Leishmania*

species of the *Viannia* subgenus circulate [57, 58].

Methods

DNA samples from reference strains of *Leishmania* and other microbial pathogens

Genomic DNA (gDNA) samples extracted from cultured promastigotes of reference

strains of *Leishmania* spp. analyzed here were retrieved from the DNA biobank of the

Leishmania research group at the Molecular Epidemiology Unit of the Instituto de

Medicina Tropical Alexander von Humboldt (IMTAvH), Universidad Peruana Cayetano

Heredia (UPCH) in Lima, Peru, and from the collection hosted by the Institute for

Scientific Research and High Technology Services (INDICASAT-AIP) in Panama.

gDNA samples isolated from cultured laboratory reference strains of other microbial

pathogens (*Trypanosoma cruzi*, *Plasmodium falciparum*, *Mycobacterium tuberculosis*)

were provided by the Infectious Diseases Research Laboratory at the UPCH and

INDICASAT-AIP. The designation and source of the strains whose gDNA were analyzed

in this study are listed in Table 1.

209   At the IMTAvH and UPCH, DNA was isolated using the High Pure PCR

210 Template Preparation Kit (Roche, Mannheim, Germany). At the INDICASAT-AIP, the

211 Wizard® Genomic DNA Purification Kit (Promega, Madison, WI, USA) was used. DNA

212 was isolated according to the manufacturer's protocol, suspended in elution buffer or TE

213 buffer and stored at -20°C until use.

215 **Table 1. Reference strains used in this work**.

Strain name	WHO code[¥]	Source
Leishmania (Viannia) braziliensis	MHOM/BR/75/M2904	IMTAvH-UPCH
Leishmania (Viannia) braziliensis	MHOM/BR/75/M2903	INDICASAT-AIP
Leishmania (Viannia) braziliensis	MHOM/PE/91/LC2043	IMTAvH-UPCH
Leishmania (Viannia) braziliensis	MHOM/PE/91/LC2177	IMTAvH-UPCH
Leishmania (Viannia) peruviana	MHOM/PE/90/HB86	IMTAvH-UPCH
Leishmania (Viannia) peruviana	MHOM/PE/90/LCA08	IMTAvH-UPCH
Leishmania (Viannia) peruviana	MHOM/PE/2005/WR-2771	INDICASAT-AIP
Leishmania (Viannia) guyanensis	MHOM/BR/1975/M4147	INDICASAT-AIP
Leishmania (Viannia) lainsoni	MHOM/BR/1981/M6426	INDICASAT-AIP
Leishmania (Viannia) panamensis	MHOM/PA/2018/BD-02	INDICASAT-AIP
Leishmania (Leishmania) amazonensis	MHOM/BR/1973/M2269	INDICASAT-AIP
Leishmania (Leishmania) mexicana	MHOM/BZ/1982/BEL21	INDICASAT-AIP
Leishmania (Leishmania) aristidesi	MORY/PA/1969/GML	INDICASAT-AIP
Leishmania (Leishmania) major	MHOM/SA/1991/WR-1088	INDICASAT-AIP
Leishmania (Leishmania) infantum	MCAN/BR/1997/P142	INDICASAT-AIP
Leishmania (Leishmania) donovani	MHOM/IN/2006/WR-2801	INDICASAT-AIP
Trypanosoma cruzi	Sylvio X10	UPCH
Trypanosoma cruzi	VT-1	UPCH
Trypanosoma cruzi	Tulahuen LacZ clone C4	UPCH
Plasmodium falciparum	HB3	INDICASAT-AIP
Mycobacterium tuberculosis	PA155-18C	INDICASAT-AIP

217 [¥]The World Health Organization (WHO) designation code for *Leishmania* strains is as follows: host (M

218 for Mammalia; HOM = *Homo sapiens*; CAN = *Canis familiaris*; ORY = *Oryzomys capito*)/country of

219 origin (BR = Brazil; BZ = Belize; IN = India; PA = Panama; PE = Peru; SA = Saudi Arabia)/year of

220 isolation/name of strain.

Patient DNA samples

Ethics statement

This study used anonymized stored DNA samples that were assigned a code and had been

isolated from different human skin ulcerative lesion specimen types, including biopsy,

lancet scraping, cytological brush, swab, and filter paper. The respective patients had

provided written informed consent for future research use of their specimens and clinical

data. Patients with clinically suspected CL were recruited at the Hospital Nacional Adolfo

Guevara Velasco (HNAGV) in Cusco, a region in Peru with endemic circulation

of *Leishmania* (*Viannia*) parasites, most frequently *L. braziliensis*, *L. guyanensis* and *L.*

lainsoni [57, 58], as part of another study between the HNAGV and UPCH (contract 095-

2018-FONDECYT-BM-IADT-AV to JA, financed by CONCYTEC and The World

Bank). The study protocol and informed consent (registration number 103155) were

reviewed and approved by the ethics committee of the UPCH (IRB approval letter 063-

05-19 dated 01/30/2019, latest renewed on 05/02/2023 with letter R-149-17-23).

DNA extraction from clinical samples prior to this study

DNA from clinical samples was isolated with the High Pure PCR Template Preparation

Kit (Roche), according to the manufacturer's protocol, suspended in elution buffer and

stored at -20°C until use.

LAMP primer design

The 18S rDNA gene (TriTrypDB ID: LbrM.27.2.208540; at

https://tritrypdb.org/tritrypdb/) and kDNA minicircles (GenBank accession no.

KY698803.1) from *L. braziliensis* MHOM/BR/75/M2904 were selected for LAMP

primer design. FASTA sequences up to 200 bp downstream and upstream to previously

reported crRNA target recognition sites for each gene [45] were uploaded to

PrimerExplorer V5 software (Eiken Chemical Co., Ltd). Three sets of external (F3 and

B3) and internal (FIP and BIP) primers were obtained for 18S rDNA, but only one for

kDNA. To select the final 18S primer set, the following features were considered: the less

likelihood of primer dimer formation (highest ΔG value), the 3' end stability for F2 and

B2 (ΔG ≤ -4 kcal/mol), the 5' end stability for F1c and B1c (ΔG ≤ -4 kcal/mol) and the

less overlap between primers and the recognition site. After that, loop primers (LF and

LB) for both target genomic regions were also designed using the PrimerExplorer V5

software. Final primer sets were ordered from Macrogen Inc. (Seoul, South Korea) and

are listed in the S1 Table.

To investigate the *in silico* specificity of the designed LAMP primers, we

downloaded all publicly available DNA sequences for each target from NCBI in May

2025. For *Leishmania* kDNA minicircle sequence analysis, a total of 1,060 sequences

from the *L.* (*Viannia*) subgenus and 965 sequences from the *L.* (*Leishmania*) subgenus

were retained and analyzed following a quality filtering process. Sequences that were

excluded contained ambiguous base pairs (e.g. 'N') exceeding 10% of the total length or

did not cover the primer binding sites. The eight LAMP primer binding regions and the

crRNA target site were manually annotated using Jalview v2.11.4.1 [59] following

multiple sequence alignment with Clustal Omega [60]. Sequence alignments are available

in the S1 File. A representative subset of 59 sequences (24 *Viannia*, 35 *Leishmania*) is

illustrated in S1 Fig to indicate sequence conservation or variations across the two

analyzed *Leishmania* subgenera. As for the 18S rDNA, 37 sequences from *Leishmania*

spp. and 272 from *Trypanosoma* spp. were aligned and analyzed using the same

bioinformatics pipeline (S2 File). A subset of 31 representative sequences (16 *Leishmania*

spp., 15 *Trypanosoma* spp.) was selected to denote sequence conservation or variations

across the two analyzed trypanosomatid genera (S2 Fig).

crRNA guide sequences and preparation

275 We used previously reported LbCas12a crRNA guide sequences targeting 18S rDNA and

276 kDNA minicircle sequences [45]. crRNA preparation from double-stranded DNA

277 templates (see S1 Table for nucleotide sequences) was performed as described previously

278 [45].

Loop-mediated isothermal amplification (LAMP) assay

We first optimized the LAMP assay reaction conditions using a commercial Bst 2.0®

DNA polymerase (New England Biolabs Inc (NEB), Massachusetts, USA; Cat no.

M0537), following the LAMP protocol as suggested by the manufacturer (NEB). The

only modification was the final total concentration of $MgSO_4$ in the reaction (6 mM Mg^{2+}

for 18S rDNA and 5 mM Mg^{2+} for kDNA). These reaction conditions were used to

evaluate the incubation time needed for optimal amplification of the target DNA, which

was tested at 2×10^2, 2×10^{-1}, and 2×10^{-3} parasite genome equivalents (GE) per reaction

to cover a wide range of target abundance. The LAMP reaction products were analyzed

by 2% agarose gel electrophoresis using SYBR Gold staining and tested downstream

using CRISPR-Cas12a assays with fluorescence readout (see below).

To facilitate master mix preparation for sample processing, LAMP reactions for

the preamplification of *Leishmania* DNA targets were performed using the WarmStart®

LAMP Kit (DNA & RNA) (NEB; Cat no. E1700). Each reaction contained 12.5 µL of

WarmStart LAMP 2X Master Mix, 8 µL of molecular biology grade water, and 2.5 µL of

10X LAMP primer mix for a single target (kDNA or 18S rDNA). Like for the LAMP

protocol using the separate Bst enzyme, the six target-specific primers (3 sets) were added

at a final concentration of 1.6 µM for forward inner and backward inner primers

(FIP/BIP), 0.4 µM for loop forward and loop backward primers (LF/LB), and 0.2 µM for

forward external and backward external primers (F3/B3). After that, we carefully added

20 µL of immersion oil over the LAMP mix to create two layers to prevent cross

contamination. Then, 2 µL of DNA template (0.26 – 40 ng, for analytical testing) was

added to the first (bottom) layer, corresponding to the LAMP mixture, bringing the final

reaction volume to 25 µL. The LAMP reaction was incubated on a heating block at 65°C

for 30 min for kDNA or for 50 min for 18S rDNA, and then stopped by incubating at

82°C for 3 min.

A positive control (*L. braziliensis* M2904 gDNA, $10^2 – 10^4$ GE as indicated in the

figure legends) and a negative amplification control (LAMP reaction without DNA

template, i.e., No-Template Control (NTC)) were included in all experiments. In the

analytical specificity testing, a negative control consisting of human gDNA from

peripheral blood mononuclear cells (PBMC) of a healthy donor (40 ng of input DNA)

was also included.

CRISPR-Cas12a assay with fluorescence readout

LbCas12a-based detection reactions were performed as described previously [45, 61, 62],

with the only modification being that a different reporter probe was used, which allows

fluorescence signal visualization on a LED transilluminator. We prepared the

ribonucleoprotein (RNP) complex 10X by mixing recombinant LbCas12a (produced in-

house [63]) with the target-specific folded crRNA (incubated at 65°C for 10 min followed

by room temperature (RT) incubation for 10 min) in a 1:1.5 molar ratio and 2 µM single-

stranded DNA (ssDNA) reporter probe (/56-FAM/TTATT/3IABkFQ/; [24]) in reaction

buffer 1X (NEBuffer 2.1 recipe, prepared in-house, without adding MgCl₂). The labeled

fluorophore/quencher probe was purchased from Macrogen Inc. (Seoul, South Korea). A

volume of 10 µL of the 10X RNP complex (pre-incubated for 10 min at RT) was loaded

into each well of a flat-bottom, black 96-well microplate (Thermo Fisher Scientific,

Waltham, MA, United States; Cat. no. 237107). Subsequently, 90 µL of the diluted

LAMP product –prepared by diluting 2 µL of the LAMP product in 106 µL of 1X reaction

buffer containing 16.7 mM $MgCl_2$– was added. The 100 µL LbCas12a *trans*-cleavage

reaction, with a final $MgCl_2$ concentration of 15 mM, was incubated and analyzed in a

fluorescence plate reader (Synergy™ H1 hybrid multi-mode reader; BioTek Instruments,

Winooski, VT, United States) for 121 min at 25°C. Fluorescence measurements were

recorded every 1 min (λex: 490 nm; λem: 525 nm) with a fluorescence gain setting of

120. For the experiments shown in S3 Fig, measurements used the Varioskan™ LUX

multimode microplate reader (Thermo Fisher Scientific).

Optimization of the CRISPR-Cas12a-based detection assay coupled with lateral

flow readout

The lateral flow assay (LFA) readout was optimized using the HybriDetect - Universal

lateral flow assay kit (Milenia Biotec GmbH, Giessen, Germany; Cat. no. MGHD 1)

according to the manufacturer's instructions. First, to optimize the reporter probe

concentration (for reducing the background signal on the T-line of the LFA strip in

negative controls), we tested the reporter at a final concentration (1X) of 500 nM, 250

nM, and 100 nM per LFA. Second, we tested the reaction buffer 1X without $MgCl_2$

(prepared in-house following the NEBuffer 2.1 recipe) as compared to the HybriDetect

universal assay buffer. Third, we tested two incubation temperatures of the Cas12a

reaction: either 25°C or 37°C, for a reaction time of 30 min or 60 min. Fourth, we

evaluated the addition of polyethylene glycol (PEG)-8000 at 2% and 4% final

concentration to the completed CRISPR-Cas12a reaction for increasing the viscosity of

the buffer, which in turn slows down lateral flow speed.

Optimized CRISPR-Cas12a-based lateral flow strip assay for clinical samples and

reference strain genomic DNA

After completion of the preamplification step, 2 µL of the LAMP product was mixed with

106 µL of 1X reaction buffer with 16.7 mM $MgCl_2$ in a 1.5 mL microcentrifuge tube.

Then, we took 90 µL of the diluted LAMP product in a new microcentrifuge tube and

added 10 µL of the 10X pre-incubated RNP complex (100 nM Cas12a: 150 nM crRNA:

1000 nM reporter probe). The lateral flow cleavage reporter probe (5'/Bio/TTATTATT/6-

FAM/3'; with terminal biotin and FAM labels in the opposite order relative to [26]) was

purchased as an HPLC-purified oligo from biomers.net GmbH (Ulm, Germany). The 100

µL LbCas12a *trans*-cleavage reaction, with a final $MgCl_2$ concentration of 15 mM, was

incubated at 37°C for 60 min in the dark. Afterward, 5 µL of PEG-8000 (2% final

concentration) was added to the reaction tube and homogenized by pipetting up and down.

A lateral flow strip (Milenia HybriDetect) was placed into the reaction tube and incubated

for 5 min at RT. Lateral flow strips were interpreted visually. LFA strip images shown

here were taken with an iPhone 13 Pro camera.

Analytical sensitivity testing

Serial dilutions of *L. braziliensis* M2904 gDNA (extracted from a promastigote culture)

to a final range of 2×10^4 to 2×10^{-3} parasite GE per reaction (encompassing the same

range of parasite GE per reaction of the standard curve used in the kDNA qPCR assay

[64]) were tested as input DNA in LAMP reactions to amplify the target gene, followed

by LbCas12a-based detection assays as described above, using a plate-based fluorescence

readout and a colorimetric lateral flow-based readout. The analytical sensitivity for each

target gene was determined based on 3 independent experiments.

Analytical specificity testing

The analytical specificity of the LAMP-CRISPR assays targeting *Leishmania* kDNA

(*Viannia* subgenus) or 18S rDNA was tested using gDNA from representative laboratory

reference strains of New World and Old World *Leishmania* species, as well as other

microbial pathogens (Table 1). Target genes were amplified by LAMP (using 20–40 ng

of input DNA) and detected by LbCas12a-based detection assays as described above,

using fluorescence-based and lateral flow-based readouts. Two independent LAMP-

CRISPR experiments were performed.

Evaluation of LAMP-CRISPR assay performance on clinical samples

Patient DNA samples extracted from skin lesion specimens were tested blindly by the

LAMP-CRISPR assays in groups of ten, plus positive and negative controls. The DNA

input for the LAMP preamplification step was 5 µL of diluted or undiluted DNA samples

(6–285 ng of input DNA; see S1 Dataset) to capture data from samples with low

Leishmania parasite load levels. The LAMP products were then detected by LbCas12a-

based detection assays as described above.

Quantitative real-time PCR (qPCR)

A qPCR assay targeting *Leishmania* kDNA minicircles was performed to detect and

quantify *Leishmania* (*Viannia*) parasites in clinical samples, using primers and cycling

conditions as described [64]. The human *ERV-3* gene was amplified in parallel using the

primers reported by Yuan *et al*. [65]; it served as an indicator of specimen adequacy and

to estimate the parasite load normalized to the number of human cell equivalents per

sample [64].

Data processing and analysis

The data collected from LAMP-CRISPR assays were analyzed as described previously

[45]. Briefly, the raw fluorescence data from each well of the LbCas12a-based assay plate

were exported to Microsoft Excel. Based on the inspection of fluorescence time-course

data from samples and controls that were run in parallel, the time point of fluorescence

accumulation for data analysis was defined (at 25-min time point for both kDNA and 18S

rDNA). The raw fluorescence data were normalized by dividing target reaction

fluorescence accumulated at the defined time point of the test sample to that of the NTC

reaction included in parallel in the same Cas12a assay plate (further called 'fluorescence

ratio'). In the analytical validation, a result was considered 'detected' if a target reaction

produced a fluorescence ratio ≥ 2 for the test sample above background (NTC). To set a

threshold cutoff value for positive signal (i.e., detection of *Leishmania*) in clinical

samples, we required that the fluorescence ratio be larger than the mean and three standard

deviations of negative clinical samples (see S1 Dataset) selected as a separate panel for

determining the cutoff. Graphs, numerical data analyses, and statistical analyses were

performed using GraphPad Prism version 10.2 (GraphPad Software, San Diego, CA,

United States).

For the diagnostic performance evaluation of the LAMP-CRISPR assays with

fluorescence readout, the sensitivity and specificity and their 95% confidence intervals

were calculated with MedCalc software [66] using kDNA real-time PCR as the reference

test. To evaluate the accuracy of the LAMP-CRISPR assays to discriminate a positive

(detected) from a negative (not detected) *Leishmania* infection status, a receiver operating

characteristic (ROC) curve was drawn and the area under the curve (AUC) with its 95%

confidence interval was calculated using GraphPad Prism version 10.2. In all statistical

tests, a *P* value of < 0.05 was considered statistically significant.

To assess the applicability of the LAMP-CRISPR assays with an LFA readout, 18

clinical samples selected for pilot testing were arbitrarily categorized into three groups

based on parasite load: low (<100 parasites/10^6 human cells), intermediate ($100 - 10,000$

parasites/10^6 human cells), and high ($>10,000$ parasites/10^6 human cells). LFA strips were

interpreted blinded to the fluorescence results.

Results

Design and optimization of LAMP-CRISPR assays

We developed two assays for the detection of *Leishmania* spp., which are based on the

most frequently used multicopy genetic markers in molecular diagnostics for

leishmaniasis: kDNA minicircles and 18S rDNA. Our assays combine LAMP with

CRISPR-LbCas12a-mediated DNA target recognition and ssDNA reporter cleavage, with

results assessed either with a fluorescence-based or lateral flow strip readout (Fig 1).

These two readouts are made possible through the use of different dual-labeled ssDNA

reporter molecules: one labeled with a fluorophore-quencher pair for real-time monitoring

of fluorescence curves over the Cas12a reaction time course on a plate reader, and the

other labeled with biotin and FAM for results to be visually read with paper-based lateral

flow strips [26].

Fig 1. Schematic representation of the workflow of LAMP-CRISPR assays for detection of *Leishmania* spp. in clinical samples. Sample preparation is performed from

skin lesion specimens taken from patients with suspected CL. The DNA samples are

subjected to LAMP amplification for just 30 min (kDNA) or 50 min (18S rDNA),

followed by Cas12a-based reactions with either a fluorescence-based or lateral flow strip

readout. Figure created with BioRender.com.

We designed LAMP primers flanking previously reported crRNA target

recognition sites [45] within *Leishmania* kDNA minicircles (S1 Fig) and 18S rDNA (S2

Fig). According to the *in silico* analyses, the kDNA primer set targets a region most

conserved within the *L.* (*Viannia*) subgenus and less conserved within the *L.* (*Leishmania*)

subgenus (S1 Fig and S1 File). *In silico* analysis of the selected 18S primer set showed

the expected conserved nature of the targeted genomic region at the *Leishmania* genus

level, whereas sequence variations were more frequent within the *Trypanosoma* genus

(S2 Fig and S2 File).

A schematic depicting the mechanism of LAMP amplification, with the resulting

LAMP amplicon containing the Cas12a crRNA target sequence is shown in Fig 2. We

optimized the LAMP assay reaction conditions using a commercial Bst 2.0 DNA

polymerase and tested the incubation time required for optimal amplification of the target

DNA. The CRISPR-Cas12a assay was used as the readout. For kDNA, the LAMP

reaction was evaluated at 4 different incubation times (10, 20, 30, and 40 min) (S3A-D

Fig). While 10 min were sufficient to amplify the target DNA sequence present at a high

quantity (2×10^2 GE) (S3A Fig), at least 20 min were required for the amplification of

low abundant target DNA (2×10^{-1} GE) (S3B Fig). On the other hand, an incubation time

of 40 min enabled the amplification of a very low quantity of the target DNA (2×10^{-3}

GE) but also resulted in a positive signal of the NTC reaction (S3D Fig), the latter

indicative of contamination. These results were corroborated through visualization of the

LAMP reaction products by agarose gel electrophoresis (S3F Fig). We thus chose an

incubation time of 30 min as the most optimal for the kDNA LAMP reaction (S3C and

S3E Fig) for further experiments. For the 18S rDNA gene, we tested the LAMP reaction

at 5 different incubation times (10, 30, 40, 50, and 60 min) (S3G-K Fig). At least 40 min

were required to amplify the target DNA present at varying levels of abundance (2×10^2

and 2×10^{-1} GE) (S3I Fig). Extending the incubation time of the LAMP reaction to 60

min allowed the amplification of very low-abundant target DNA (2×10^{-3} GE) but also

resulted in NTC contamination (1 out of 2 replicates of the NTC reaction showed a

positive signal) (S3K Fig). CRISPR-Cas12a-based detection of LAMP amplicons could

effectively discriminate between specific amplification products and non-specific

amplification. The latter was observed, for instance, at the incubation times of 10 min and

40 min in the NTC reaction by agarose gel electrophoresis (S3M Fig) but did not result

in false positives in the Cas12a assay (S3G and S3I Fig). On the basis of these results, we

selected an incubation time of 50 min for the 18S LAMP reaction (S3J and S3L Fig) for

further experiments.

Fig 2. Schematic representation of the LAMP reaction, highlighting the location of

the crRNA target sequence in the target DNA. (A-E) Steps in the LAMP reaction to

amplify the target DNA. The eight annealing locations of the six LAMP primers are

shown. The primers were designed to target unique sequences within a conserved region

of *Leishmania* kDNA minicircles (S1 Fig) or nuclear 18S rDNA (S2 Fig). The crRNA

target sequence and protospacer adjacent motif (PAM) site in the target DNA are shown.

For simplicity, the locations of both crRNA target sites are depicted in the same graph

(actually, the LAMP reaction is performed separately for each target). Figure adapted

from [14, 67] and created with BioRender.com.

The CRISPR-Cas12a assay is based on purified recombinant LbCas12a [63]. For

the fluorescence-based assay, we used optimized conditions as described previously [45,

61, 62] and a quenched fluorescent ssDNA reporter [24]. We optimized here the

performance of the Cas12a-based LFA readout by testing varying concentrations of the

biotin-FAM reporter probe as well as the influence of the assay buffer, incubation

temperature and reaction time of the Cas12a assay, and PEG-8000 addition. The optimal

conditions identified involved: using the reporter probe at a final concentration (1X) of

100 nM in our in-house Cas12a reaction buffer 1X (which performed comparable to the

HybriDetect universal assay buffer); incubating the Cas12a reaction at 37°C for 60 min;

and adding 2% PEG-8000 to the completed Cas12a reaction (S4 Fig).

Analytical validation of LAMP-CRISPR assays

We then assessed the analytical sensitivity of each primer set-crRNA combination using

serial dilutions of *L. braziliensis* M2904 gDNA extracted from a promastigote culture.

The kDNA LAMP-CRISPR assay displayed positive *L. braziliensis* detection down to 2

$\times 10^{-1}$ GE per reaction, both with a fluorescence readout (Fig 3A) and a LFA readout (Fig

3B). Visualization of the kDNA LAMP products on an agarose gel confirmed the

presence of ladder-like bands indicative of a successful LAMP reaction (Fig 3C),

consistent with the Cas12a-based detected amplicon samples (Fig 3A and 3B). We found

a similar analytical sensitivity for the 18S LAMP-CRISPR assay, as detection of at least

2×10^{-1} GE/reaction was achieved with a fluorescence-based readout (Fig 3D) and a LFA

readout (Fig 3E). The analysis of the 18S LAMP products by agarose gel electrophoresis (Fig 3F) was consistent with the Cas12a assay results (Fig 3D and 3E). The no-template control (NTC) tested in parallel in each LAMP-CRISPR assay showed a background signal in the Cas12a fluorescence-based assay (Fig 3A and 3D, see the two lowest GE input amounts whose fluorescence ratio is 1 given that the denominator is the NTC signal). Likewise, the NTC did not exhibit a band (or the band observed was faint) at the test line in the lateral flow strips (Fig 3B and 3E). This ruled out the possibility of cross-contamination and non-specific amplification.

Fig 3. Analytical sensitivity testing of kDNA and 18S LAMP-CRISPR assays. Serial dilutions of *L. braziliensis* M2904 gDNA encompassing 2×10^4 to 2×10^{-3} genome equivalents (GE) per reaction were subjected to LAMP amplification, followed by Cas12a-based reactions for the kDNA (A-C) or 18S rDNA (D-F) target. (A, D) Normalized fluorescence signals (fluorescence ratio) from Cas12a reactions (i.e., fluorescence signals taken at $t = 25$ min in the test sample relative to the NTC). Fluorescence measurements were taken on the Synergy H1 plate reader. Data are represented as mean $\pm$ SD (n = 3 independent amplification and detection runs). The X-axis has a logarithmic scale. A fluorescence ratio ≥ 2 is considered detected. (B, E) Cas12a reactions were performed using a biotin-FAM reporter molecule and visualized on lateral flow strips. Uncleaved reporter molecules are captured at the first detection line (control line), whereas collateral Cas12a cleavage activity generates a signal at the second detection line (test line). The arrow indicates the direction of flow. Two independent amplification and detection runs (r1 and r2) were analyzed. (C, F) LAMP reaction products (5 µL) visualized by 2% agarose gel electrophoresis ran at 100 V for 1 h using

SYBR Gold staining. L, GeneRuler 100 bp (C) or 100 bp Plus (F) DNA ladder. NC,

negative control (NTC, no-template control). Since space was tight on the agarose gel

images, we had to abbreviate the labels for each lane. For instance, "10^4" actually

represents "2×10^4" as indicated in the fluorescence (A, D) and LFA (B, E) panels.

Assay specificity testing (S5 Fig) was performed using gDNA samples isolated

from cultured laboratory reference strains of *Leishmania* spp., phylogenetically close

pathogens, and pathogens that cause similar lesions to CL or can coinfect the same host

(Table 1). The kDNA LAMP-CRISPR assay consistently detected representative strains

of the *Leishmania* (*Viannia*) species present in our sample set (10 of 10; Fig 4A). This

was expected given that our designed kDNA-crRNA targets a region of kDNA

minicircles conserved within the *L.* (*Viannia*) subgenus ([45] and S1 Fig). Additionally,

the assay detected 2 out of 6 tested strains belonging to the *L.* (*Leishmania*) subgenus (Fig

4A). The 18S LAMP-CRISPR assay showed pan-*Leishmania* detection ability (Fig 4A).

In both kDNA and 18S LAMP-CRISPR assays, no cross-reactivity was observed for

related trypanosomatid (*T. cruzi*) strains and other protozoan (*P. falciparum*) and bacterial

(*M. tuberculosis*) pathogens tested (Fig 4A). Also, the negative control with human

gDNA as template was not detected (Fig 4A). The analytical specificity was also assessed

with an LFA readout, where strips were interpreted by visual inspection on the basis of

the presence or absence of test bands. Three *L.* (*Viannia*) strains used as positive controls

were detected (i.e., showing a strong T-line and a very weak or missing C-line) by both

LAMP-CRISPR assays (Fig 4B, strips # 3-5). The negative controls (human gDNA and

NTC) had a negative test result (Fig 4B, strips # 1 and 2). There was no cross-reactivity

to other microbial pathogens tested (Fig 4B, strips # 6-10, which show a strong C-line and a faint (or absent) T-line, similar to the negative controls).

Fig 4. Analytical specificity testing of kDNA and 18S LAMP-CRISPR assays. The specificity of the kDNA and 18S LAMP-CRISPR assays was evaluated using gDNA from reference strains of *Leishmania* spp. and other microbial pathogens (see Table 1 and S5 Fig). (A) Heat maps depicting LAMP-CRISPR fluorescence-based detection data from tested reference strain samples. The color scale represents normalized fluorescence signals from Cas12a reactions (i.e., fluorescence signals taken at $t = 25$ min in the test sample relative to the NTC) for *Leishmania* kDNA and 18S rDNA targets. The fluorescence ratio values from 2 independent assay repeats were entered into GraphPad; the mean of these replicates is displayed. A fluorescence ratio ≥ 2 is considered detected. (B) Cas12a reactions were performed using a biotin-FAM reporter molecule and visualized on lateral flow strips. Uncleaved reporter molecules are captured at the first detection line (control line), whereas collateral Cas12a cleavage activity generates a signal at the second detection line (test line). The arrow indicates the direction of flow. Top panel: kDNA LAMP-CRISPR assay; bottom panel: 18S LAMP-CRISPR assay. Negative controls: HC, human control (gDNA from PBMCs of a healthy donor) (strip # 1); NC, no-template control (NTC) (strip # 2). Positive controls: Lbra, *L. braziliensis* M2904 (strip # 3); Lguy, *L. guyanensis* M4147 (strip # 4); Lper, *L. peruviana* LCA08 (strip # 5). Non-related microbes: Mtb, *M. tuberculosis* PA155-18C (strip # 6); Pf, *P. falciparum* HB3 (strip # 7). *T. cruzi* (Tc) strains: Tulahuen, Sylvio X10, and VT-1 (strips # 8-10).

Performance evaluation of LAMP-CRISPR assays with clinical samples

Positive patient samples exhibited robust fluorescence curves in the Cas12a assay indicating the presence of *Leishmania* kDNA (S6A Fig) or 18S rDNA (S6B Fig) molecules. These results were consistent with the respective positive LAMP reactions as visualized on an agarose gel (S6C and S6D Fig). We noted that the analysis of LAMP products by agarose gel electrophoresis can sometimes give ambiguous (or difficult to interpret) results. For instance, ladder-like bands were observed for samples S72 and S09 amplified by the 18S LAMP assay (S6D Fig), although the band pattern was different from the one observed for true positive reactions. This was clearly resolved by the Cas12a-based assay on those amplicons, which confirmed that S72 and S09 were negative for *Leishmania* 18S rDNA molecules (S6B Fig).

We next evaluated the performance of our LAMP-CRISPR fluorescence-based detection assays using gDNA from 90 clinical samples of skin lesions. An in-house qPCR assay [64] targeting a kDNA minicircle region conserved among *Leishmania* (*Viannia*) species [68] served as the reference test. Of the 90 samples, 55 were *Leishmania*-positive and 35 were negative by qPCR.

To determine the cutoff value for discriminating between *Leishmania*-positive and –negative samples by the LAMP-CRISPR assays, we used the mean of the fluorescence ratio of negative samples + 3SD. To this end, an independent panel of negative samples was used: n = 19 for the kDNA assay and n = 10 for the 18S assay (S1 Dataset). A higher number of negative samples was needed for the former to capture the inter-assay variation in raw fluorescence signal from the Cas12a reaction that was evident over different periods of sample testing (S1 Dataset). The determined cutoff value was 1.46 for the kDNA assay and 1.30 for the 18S assay (S1 Dataset).

The kDNA LAMP-CRISPR assay detected 50 (90.9%) of 55 qPCR-positive samples (Fig 5 and 6A, Table 2, and S1 Dataset). Of these, the 5 samples not detected by kDNA LAMP-CRISPR (coded 3, 5, 6, 28 and 71) harbored low parasite loads ($\leq$20 parasites/10^6 human cells) (Fig 6B and S1 Dataset), corresponding to 10^{-2} to 10^{-3} parasite GE/reaction (S1 Dataset, see "Parasite equivalents" data in the worksheet "qPCR_CS"). The 18S LAMP-CRISPR assay detected 40 (72.7%) of 55 qPCR-positive samples (Fig 5 and 6C, Table 2, and S1 Dataset). Of these, the 15 samples not detected by 18S LAMP-CRISPR contained a parasite load of $\leq$150 parasites/10^6 human cells (Fig 6D and S1 Dataset), which corresponded to 10^{-1} to 10^{-3} parasite GE/reaction (S1 Dataset, see "Parasite equivalents" data in the worksheet "qPCR_CS"). Both LAMP-CRISPR assays achieved 100% specificity (Table 2). The complete dataset of this study is presented in the S1 Dataset.

A ROC curve analysis was used to assess the performance of each assay in distinguishing *Leishmania*-positive and -negative clinical samples, with AUC values of 0.973 for the kDNA LAMP-CRISPR assay (Fig 7A) and 0.876 for the 18S LAMP-CRISPR assay (Fig 7B).

Fig 5. Evaluation of kDNA and 18S LAMP-CRISPR assay performance on clinical samples. Heat maps showing LAMP-CRISPR fluorescence-based detection data from tested clinical samples (n = 90). The color scale represents normalized fluorescence signals from Cas12a reactions (i.e., fluorescence signals taken at $t = 25$ min in the test sample relative to the NTC) for *Leishmania* kDNA and 18S rDNA targets. Samples are coded as 1-90 ('Code_UPC' as indicated in the S1 Dataset). PC, positive control (*L. braziliensis* M2904 gDNA, $10^3 - 10^4$ genome equivalents); NC, no-template control

(NTC) of the LAMP reaction. The cutoff value was 1.46 for the kDNA assay and 1.30

for the 18S assay (mean of the fluorescence ratio of negative clinical samples used to

calculate cutoff values + 3SD; see the S1 Dataset). The Cq values corresponding to the

kDNA qPCR assay (reference test) are shown. For Cq values, the letter "U" denotes

undetermined; X, not applicable.

Fig 6. Evaluation of kDNA and 18S LAMP-CRISPR assay performance on clinical

samples: analysis across the range of parasite load levels. (A, C) Scatter plots showing

normalized fluorescence signals from Cas12a reactions (i.e., fluorescence signals taken

at $t = 25$ min in the test sample relative to the NTC) for *Leishmania* kDNA (A) and 18S

rDNA (C) targets in clinical samples (n = 90; data shown in Fig 5 and S1 Dataset) versus

Cq values determined by kDNA qPCR. (B, D) Scatter plots showing normalized

fluorescence signals from Cas12a reactions for *Leishmania* kDNA (B) and 18S rDNA

(D) targets in clinical samples versus the estimated parasite load in quantifiable samples

(n = 55). The parasite load is expressed as the number of *Leishmania* parasites/10^6 human

cells. The horizontal dotted lines represent the LAMP-CRISPR assay cutoff value (mean

of the fluorescence ratio of negative clinical samples + 3SD; see the S1 Dataset): 1.46 for

the kDNA assay and 1.30 for the 18S assay.

Table 2. Diagnostic performance of LAMP-CRISPR assays with fluorescence readout for *Leishmania* DNA detection compared with the kDNA qPCR assay

	kDNA qPCR		% (95% CI)	
Test	Positive (n = 55)	Negative (n = 35)	Sensitivity	Specificity
kDNA LAMP-CRISPR			90.91 (80.05-96.98)	100.00 (90.00-100.00)
Positive	50	0		
Negative	5	35		
18S LAMP-CRISPR			72.73 (59.04-83.86)	100.00 (90.00-100.00)
Positive	40	0		
Negative	15	35		

Results of the statistical analysis of diagnostic test performance conducted with the MedCalc software version 23.0.1. (https://www.medcalc.org/calc/diagnostic_test.php)

Fig 7. Evaluation of kDNA and 18S LAMP-CRISPR assay performance on clinical samples: ROC curve analysis. ROC curve analysis performed using the fluorescence ratio values of the kDNA LAMP-CRISPR assay (A) or the 18S LAMP-CRISPR assay (B) from tested clinical samples (n = 90; data shown in Fig 5 and S1 Dataset), with the *Leishmania* infection status (positive/negative) as determined by kDNA qPCR (reference test). The area under the curve (AUC) and corresponding 95% confidence interval (calculated using the Wilson/Brown method) are shown. The diagonal dotted line corresponds to the null hypothesis with AUC of 0.5, in which the accuracy of a diagnostic test is no different from random chance.

We also assessed the applicability of the LAMP-CRISPR assays with an LFA

readout on clinical samples. To this end, we performed pilot testing on gDNA extracted

from a representative group of clinical samples (n = 18) encompassing a wide range of

parasite load levels as determined by the kDNA qPCR assay. Lateral flow testing results

were consistent across two assay repeats per sample (n = 8; S7 Fig), indicating robust

assay reproducibility. Subsequently, we expanded the evaluation to include 10 additional

clinical samples, thus analyzing a total of 18 specimens (Fig 8). Samples that tested

positive by the kDNA LAMP-CRISPR assay (16/18 = 88.9%) included the 3 parasite load

categories: low (4 of 6 tested), intermediate (6 of 6), and high (6 of 6) (Fig 8). These LFA

results were 100% concordant with the fluorescence-based readout (Fig 8 and S1

Dataset). The 18S LAMP-CRISPR assay with LFA readout detected *Leishmania* DNA in

72.2% (13/18) of the examined samples, which had parasite load levels defined as: low

(2 of 6 tested), intermediate (5 of 6), and high (6 of 6) (Fig 8). One sample (coded 12) out

of the 18 tested samples (5.6%) by the 18S assay showed discordant results between LFA

and fluorescence-based readouts (Fig 8), with this associated with a low parasite load

(56.6 parasites/10^6 human cells) (S1 Dataset). The two examined DNA samples from non-

leishmaniasis patients (i.e., kDNA qPCR-negative; samples 09 and C7) tested negative

by both LAMP-CRISPR assays (Fig 8 and S7 Fig).

Fig 8. Pilot testing of kDNA and 18S LAMP-CRISPR assays on clinical samples

using a lateral flow readout. A representative subset of clinical samples with varying

parasite load levels was tested with kDNA and 18S LAMP-CRISPR assays using a LFA

readout. Visualization on the lateral flow strips (Milenia GenLine HybriDetect strips) was

achieved through the cleavage of the biotin-FAM reporter molecule. C, control line; T,

test line. The results of the fluorescence-based readout of the LAMP-CRISPR assays (+,

detected; -, not detected, on the basis of the estimated cutoff; see S1 Dataset) as well as

the Cq values of the kDNA qPCR are indicated below each strip. Controls included DNA

samples from two non-leishmaniasis patients (i.e., kDNA qPCR-negative; samples 09 and

C7), a positive control (PC, 2×10^2 genome equivalents from *L. braziliensis* M2904

gDNA), a human negative control (HC, 20 ng of human PBMC gDNA), and a no-

template control (NTC) of the LAMP reaction.

Discussion

The pressing need for new diagnostic tools has been identified as a priority in the World

Health Organization (WHO) 2030 road map to support the control and elimination of

neglected tropical diseases [69]. Among them, leishmaniasis belongs to the category of

the most neglected ones as it entails a group of diseases with a large negative impact on

people living in endemic rural areas, who are often economically disadvantaged and do

not have access to an early, correct disease diagnosis that would enable timely adequate

treatment. PCR-based molecular diagnostics provide the most sensitive and specific tools

for *Leishmania* detection and are pivotal for early disease diagnosis, discrimination of

Leishmania species, detection of asymptomatic infections, and epidemiological

surveillance [70]. Besides their use in centralized laboratories, the progress in the

automation and simplification of the workflow from sample preparation to target

amplification and detection (result readout) steps has made molecular diagnostics more

suitable and accessible for resource-limited settings in the form of near-PoC tests [71].

Examples of promising formats include the *Leishmania* OligoC-TesT (a PCR-

oligochromatographic test) [72, 73] and a PCR-based method applied directly on EDTA

blood for the diagnosis of VL, where the PCR is run on a portable miniPCR device and

the labeled PCR products are detected with a lateral flow immunoassay [74]. Other recent

advances have been facilitated by the incorporation of isothermal NAATs, such as LAMP

and RPA, combined with lateral flow detection or other portable devices [75-79]. Among

the most promising approaches is the integration of isothermal NAATs with CRISPR

technology, which has fostered the development of a new generation of molecular

diagnostics with the potential to advance toward near-PoC applications in low-resource

settings [80].

In the present study, we aimed to contribute with the development of LAMP-

coupled CRISPR-Cas12a assays for molecular detection of *Leishmania* spp. We designed

new LAMP primer sets that flank previously reported crRNA target sites [45] within two

commonly used multicopy regions of the *Leishmania* genome: the 18S rDNA and kDNA

minicircles. We harnessed the CRISPR-Cas12a system as the detection method to avoid

possible false positive results caused by non-specific amplification in the LAMP reaction

and thereby improve the assay's specificity. The assay process can be completed within

1.5 h, with results readable via either of the two optimized readouts: a fluorescence-based

readout (suitable for laboratories with minimal molecular biology equipment such as a

blue light transilluminator or a handheld fluorimeter) and a visual readout on lateral flow

strips (to simplify the use of these assays). We report on the analytical validation and

initial performance evaluation of our assays in clinical samples under controlled

conditions in a research laboratory setting. With these achievements, compared to our

previous proof-of-concept PCR-CRISPR assays [45], we aim to pave the way towards

making CRISPR-based diagnostics accessible in a testing kit format for the diagnosis of

leishmaniasis in rural endemic areas.

Here, in keeping with our *in silico* primer and crRNA design within conserved

target genomic regions, the analytical validation demonstrated the ability of the 18S

LAMP-CRISPR assay to achieve pan-*Leishmania* detection, whereas the kDNA LAMP-CRISPR assay reliably detected species belonging to the *Leishmania* (*Viannia*) subgenus. The kDNA assay also detected certain strains from the analyzed species of the *L.* (*Leishmania*) subgenus, specifically *L. mexicana* from Central America and *L. donovani* from the Old World. These results reflect both the similarity and variations in mitochondrial kDNA minicircle sequences between the two subgenera (see S1 Fig). Furthermore, our assays showed no cross-reactivity against other pathogens tested, which co-circulate in the same geographic regions and can thus coinfect the same human host, such as *T. cruzi* (a closely related trypanosomatid), *P. falciparum*, and *M. tuberculosis*, or cause cutaneous lesions similar to CL (*M. tuberculosis*) [81]. Our LAMP-CRISPR assays achieved high analytical sensitivity on serially diluted DNA from the *L. braziliensis* M2904 strain, with a detection level equivalent to 0.2 parasites per reaction. This detection sensitivity (below one parasite genome equivalent) compares well with that of the reference kDNA qPCR assay (5×10^{-3} genome equivalents per reaction; [64]), which is clinically relevant.

To explore the performance of our LAMP-CRISPR assays to detect *Leishmania* DNA in clinical samples, we evaluated a blinded panel of human skin lesion samples (n= 90) from patients enrolled in the Cusco region of Peru, where CL is caused by *L.* (*Viannia*) species. Both LAMP-CRISPR assays with a fluorescence readout attained good diagnostic performance, with sensitivity rates of 90.9% for kDNA and 72.7% for 18S rDNA, and a specificity of 100%, compared to the reference kDNA qPCR assay. Discrepancies between the two methods corresponded to samples with low parasite loads (S1 Dataset). Overall, LAMP-CRISPR assay results for the subgroup of samples tested with both fluorescence-based and lateral flow strip readouts were concordant. The 18S LAMP-CRISPR assay showed a somewhat reduced sensitivity when applied to clinical

samples. This is likely related to the differences in target copy number: *Leishmania*

parasites present an estimated 10 to 170 copies of the nuclear 18S rDNA region per

genome [82, 83], while they harbor about 10,000 copies of extrachromosomal kDNA

minicircles per cell [84].

Several studies have developed prototype LAMP assays for detecting *Leishmania*

infections in diagnosing human VL, CL, and post-kala-azar dermal leishmaniasis

(PKDL), as well as in domestic animal reservoirs (dogs) and sand flies. They target

multicopy genomic regions, such as kDNA minicircles [85-87], the 18S rRNA gene [88-

90], the ITS1 region in the rDNA array [91], and cysteine proteinase B (*cpb*) genes [92].

These assays proved to be highly sensitive for the detection of VL- and CL-causing

Leishmania species (at the genus, species complex, or species level, depending on the

target used), underscoring their potential value as diagnostic and surveillance tools in

endemic settings. With the genus-specific targets, because of their high sequence

conservation among the Trypanosomatidae, some nonspecific results were observed. For

instance, the study of Adams *et al*. [88] reported on a LAMP assay based on 18S rDNA

that was unable to discriminate between infections with *Leishmania*, *T. brucei*, and *T.*

cruzi. Since the diseases caused by these related pathogens differ in clinical presentation,

their differential diagnosis can be made on clinical symptoms and confirmed using a

species-specific LAMP assay designed for this purpose [88]. In this study, when we tested

our 18S LAMP primer set - crRNA combination, no cross-reactivity was observed with

DNA from 3 *T. cruzi* strains belonging to different genetic lineages known as discrete

typing units (DTUs), namely DTU TcI (Sylvio X10 strain), DTU TcIV (VT-1 strain), and

DTU TcVI (Tulahuen LacZ clone C4 strain). Our results demonstrate the high analytical

specificity of the LAMP-CRISPR assay towards *Leishmania* spp. We also noted that

integrating LAMP amplification with downstream CRISPR-based detection improved

discrimination between positive and negative amplification results, as shown in previous

studies [37, 56]. This outcome is due to the LAMP-coupled CRISPR assays offering two

layers of specificity: the first one enabled by using 4 to 6 LAMP primers that selectively

target 6 to 8 distinct regions in the target DNA, and the second one due to the crRNA-

guided Cas12a-mediated target sequence recognition [23]. An optimization to improve

the LAMP assay specificity involves incorporating a probe-specific detection readout

[18], as illustrated in the study by Ruang-Areerate *et al.* [93] aimed at detecting

asymptomatic *Leishmania* infections in HIV-infected patients.

The LAMP technology is commercially available and delivered, such as the

Leishmania detection kit (Loopamp™ *Leishmania* Detection Kit; Eiken Chemical Co.,

Ltd., Japan), which does not require cold-chain storage. This kit targets kDNA minicircles

and 18S rDNA in the same reaction to enable pan-*Leishmania* detection based on the

LAMP assay developed by Adams *et al.* [94]. The diagnostic performance evaluation of

this kit in different endemic areas around the world has demonstrated its high sensitivity

and specificity for the diagnosis of VL [22, 76, 94-96], CL [22, 94, 97, 98], and PKDL

[99], underscoring its potential for implementation in primary healthcare facilities.

Undoubtedly, the DNA extraction method can impact LAMP assay performance when

testing clinical samples. As shown in the study by Ghosh *et al.* [99], a lower efficiency of

LAMP to diagnose PKDL was observed when the LAMP reaction was performed using

crude DNA obtained by a simple in-house boil and spin protocol compared to DNA

extracted by a commercial silica column-based (Qiagen) kit (67.2% vs. 89.7% sensitivity,

respectively). Further, a recent study found a compromised sensitivity (48.4%) of the

Leishmania LAMP kit for the diagnosis of CL in Ethiopia, possibly due to a primer

mismatch with the *L. aethiopica* 18S rDNA target [100]. This finding points out the need

to extensively validate existing LAMP assays in diverse clinical contexts and

epidemiological scenarios in different geographical areas to confirm their effectiveness

in detecting local parasite variants that are circulating. The same applies to our new

LAMP-CRISPR assays.

Combining highly sensitive isothermal amplification with the notable highly

specific CRISPR-Cas12a system is an approach that has been applied for detecting

pathogenic trypanosomatids. For example, Wiggins *et al*. [46] developed proof-of-

concept RPA-coupled CRISPR-Cas12a assays that target kDNA maxicircles for

Leishmania spp. detection. They have recently adapted their assays into a

multichambered device to obtain a rapid nucleic acid diagnostic tool that does not require

electricity or instrumentation, a promising development for diagnostic applications in

low-resource settings [101]. In another study, Yang *et al*. [47] developed a one-tube RPA-

CRISPR/Cas12a assay that targets the *Leishmania Kmp11* gene. The assay process can

be completed within 50 min, with the fluorescent signal of reaction tubes observed

visually under blue light illumination. Their assay has been evaluated on simulated

clinical samples, yielding a sensitivity of 97.9% and a specificity of 100%. Ortiz-

Rodríguez *et al*. [50] developed a platform for *T. cruzi* detection, which was validated on

samples from reservoirs and insect vectors. It employs PCR or RPA followed by

CRISPR-Cas12a-based detection. Of 3 nuclear target genes evaluated, namely

cytochrome B (*Cytb*), the 18S rRNA gene, and histone H2A, only the former (*Cytb*)

resulted in a workable CRISPR-based assay since no mutations were found in the chosen

target site during testing of *T. cruzi* DNA extracted from the intestine of triatomine

vectors. Furthermore, the authors designed a portable prototype device (called TropD-

Detector) for fluorescence results discrimination, suitable for low-resource settings.

Guarnizo *et al*. [56] designed a LAMP-CRISPR/Cas12a assay that targets a highly

conserved region in the nuclear *HSP70* gene to specifically detect *T. cruzi* in the context

of acute Chagas disease diagnosis in endemic countries. They evaluated the assay in

clinical samples from 100 infants born to Chagas-positive mothers in Bolivia, achieving

a sensitivity of 77.27% and a specificity of 100% compared to a TaqMan-based qPCR

assay that targets satellite DNA.

Our study shows that LAMP-coupled CRISPR-Cas12a assays are an effective

alternative method for detecting *Leishmania* infections in different non-invasive and

invasive specimens (S1 Dataset) from human skin lesions. While kDNA LAMP primers

previously reported were for a *L. donovani* complex-specific assay [94] or for a *L.*

amazonensis-specific assay [87], our kDNA LAMP-CRISPR assay (specifically the

crRNA design) exploited a kDNA minicircle region conserved in the New World species

of the *Leishmania* (*Viannia*) subgenus ([45] and S1 Fig). Our pan-*Leishmania* 18S

LAMP-CRISPR assay is expected to be capable of detecting various parasite species from

both the New and Old World (S2 Fig). Our findings encourage further evaluation and

validation of both assays in different geographical areas. Besides, our assays have the

potential to be adapted in future work to address the ASSURED/REASSURED criteria

for a diagnostic test suitable for adoption across different healthcare levels, which require

assays to be affordable, sensitive, specific, user-friendly, robust and rapid, as well as

equipment-free (or operating with minimal equipment), deliverable to those who need

them, with real-time connectivity, and workable on easily collected specimens [102, 103].

Sample preparation is one of the challenges in molecular assay implementation in

resource-limited settings [104]. Further research is needed to optimize rapid DNA

extraction protocols, such as boil-spin [99] and SpeedXtract (a magnetic bead-based

method) [105], combined with a streamlined CRISPR assay workflow to move forward

to a near-PoC nucleic acid-based diagnostic assay for CL and other forms of

leishmaniasis. Both LAMP and CRISPR reactions are compatible with freeze-drying

(lyophilization), which improves reagent stability for easy transport and storage at room

temperature and may reduce contamination risks [106]. This improvement can also

facilitate the preparation of the assays in a pre-designed kit format, enabling a portable

assay setup for resource-limited settings. Therefore, the impact of freeze-drying reagents

on the performance of our assays needs to be evaluated in future work. Incorporating

these refinements into our assay procedure, along with user-friendly devices, such as the

LFA strips or a handheld fluorimeter, would allow its adoption in minimally-equipped

laboratories in endemic regions, and may be incorporated in a mobile suitcase laboratory.

The latter approach has been explored with a RPA assay in field studies conducted in

Asia, showing promising performance for VL, PKDL, and CL diagnosis in endemic

settings [105, 107, 108]. After further optimization and validation, we envisage that our

LAMP-CRISPR assays may become valuable tools for providing rapid testing results

directly in the affected regions, thereby mitigating delays associated with testing in

centralized laboratories. CRISPR-based assays could also have a considerable role in

epidemiological studies, in providing real-time surveillance data. Further, an approach

for future work that offers the potential to be impactful in resource-limited endemic

settings entails the integration of our assays with recent developments in lab-on-chip

systems, such as a paper-based LAMP-CRISPR integrated diagnostic platform (PLACID)

[37]. This paper-based device uses freeze-dried LAMP and CRISPR reagents, where

nucleic acid amplification and CRISPR reactions are performed successively without

fluid transfer using paper microfluidics. A smartphone-based protocol allows the

fluorescent detection of nucleic acid targets. This platform showed robust performance

for bacterial and viral pathogen target detection, with no false positives observed [37].

These are well-known refinements to consider in future assay development efforts.

Indeed, we noticed that our current two-step LAMP-CRISPR open assay format

intrinsically carries the risk of cross-contamination during sample transfer from tube-

based (LAMP) to plate-based (CRISPR) reactions, as reported in other studies [106].

In conclusion, we developed novel LAMP-CRISPR assays for the molecular

detection of *Leishmania*, targeting two multicopy genomic regions: 18S rDNA for pan-

Leishmania detection and a kDNA minicircle region conserved among New World *L.*

(*Viannia*) species. By integrating LAMP with CRISPR-Cas12a technology, the assays

enable accurate detection, with results readout via fluorescence or lateral flow strips, the

latter aimed at facilitating a simpler workflow. Analytical validation and initial

performance testing on clinical samples demonstrated high sensitivity and specificity,

underscoring the assays' potential as effective alternatives for detecting *Leishmania*

infections. With further optimization and validation, these prototype assays hold promise

as next-generation molecular tools with great potential to improve the diagnosis and

surveillance of leishmaniasis in endemic regions, thereby supporting One Health

strategies for disease control.

References

1. World Health Organization. Leishmaniasis. World Health Organization: WHO.

2023.   Available   from: https://www.who.int/news-room/fact-

sheets/detail/leishmaniasis

2. Pan American Health Organization. Leishmaniasis. Pan American Health

Organization: PAHO.   2017.   Available   from:

https://www3.paho.org/hq/dmdocuments/2017/2017-cha-leishmaniasis-

factsheet-work.pdf

3. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis

worldwide and global estimates of its incidence. PLoS One. 2012;7(5):e35671.

4. Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet. 2018 Sep

15;392(10151):951-970.

5. Pan American Health Organization. Leishmaniasis: Epidemiological Report for

the Americas. No.12. 2023 Dec 21. Available from:

https://iris.paho.org/handle/10665.2/59155

6. Scott P, Novais FO. Cutaneous leishmaniasis: immune responses in protection

and pathogenesis. Nat Rev Immunol. 2016 Sep;16(9):581-92.

7. Kaye PM, Cruz I, Picado A, Van Bocxlaer K, Croft SL. Leishmaniasis

immunopathology-impact on design and use of vaccines, diagnostics and drugs.

Semin Immunopathol. 2020 Jun;42(3):247-264.

8. Reimão JQ, Coser EM, Lee MR, Coelho AC. Laboratory Diagnosis of Cutaneous

and Visceral Leishmaniasis: Current and Future Methods. Microorganisms. 2020

Oct 22;8(11):1632.

9. Van der Auwera G, Dujardin JC. Species typing in dermal leishmaniasis. Clin

Microbiol Rev. 2015 Apr;28(2):265-94.

10. Akhoundi M, Downing T, Votýpka J, Kuhls K, Lukeš J, Cannet A, et al.

Leishmania infections: Molecular targets and diagnosis. Mol Aspects Med. 2017

Oct;57:1-29.

11. Mesa LE, Manrique R, Muskus C, Robledo SM. Test accuracy of polymerase

chain reaction methods against conventional diagnostic techniques for Cutaneous

Leishmaniasis (CL) in patients with clinical or epidemiological suspicion of CL:

Systematic review and meta-analysis. PLoS Negl Trop Dis. 2020 Jan

21;14(1):e0007981.

12. Bharadwaj M, Bengtson M, Golverdingen M, Waling L, Dekker C. Diagnosing

point-of-care diagnostics for neglected tropical diseases. PLoS Negl Trop Dis.

2021 Jun 17;15(6):e0009405.

13. Oliveira BB, Veigas B, Baptista PV. Isothermal Amplification of Nucleic Acids:

The Race for the Next "Gold Standard." Front. Sens. 2021 Sep 28;2:752600.

14. Notomi T, Okayama H, Masubuchi H, Yonekawa T, Watanabe K, Amino N, et

al. Loop-mediated isothermal amplification of DNA. Nucleic Acids Res. 2000 Jun

15;28(12):E63.

15. Nagamine K, Watanabe K, Ohtsuka K, Hase T, Notomi T. Loop-mediated

isothermal amplification reaction using a nondenatured template. Clin Chem.

2001 Sep;47(9):1742-3.

16. Mori Y, Nagamine K, Tomita N, Notomi T. Detection of loop-mediated

isothermal amplification reaction by turbidity derived from magnesium

pyrophosphate formation. Biochem Biophys Res Commun. 2001 Nov

23;289(1):150-4.

17. Mori Y, Hirano T, Notomi T. Sequence specific visual detection of LAMP

reactions by addition of cationic polymers. BMC Biotechnol. 2006 Jan 10;6:3.

18. Phillips EA, Moehling TJ, Bhadra S, Ellington AD, Linnes JC. Strand

Displacement Probes Combined with Isothermal Nucleic Acid Amplification for

Instrument-Free Detection from Complex Samples. Anal Chem. 2018 Jun

5;90(11):6580-6586.

19. Atçeken N, Yigci D, Ozdalgic B, Tasoglu S. CRISPR-Cas-Integrated LAMP.

Biosensors (Basel). 2022 Nov 17;12(11):1035. doi: 10.3390/bios12111035.

20. Nzelu CO, Kato H, Peters NC. Loop-mediated isothermal amplification (LAMP):

An advanced molecular point-of-care technique for the detection of *Leishmania*

infection. PLoS Negl Trop Dis. 2019 Nov 7;13(11):e0007698.

21. Erber AC, Sandler PJ, de Avelar DM, Swoboda I, Cota G, Walochnik J. Diagnosis

of visceral and cutaneous leishmaniasis using loop-mediated isothermal

amplification (LAMP) protocols: a systematic review and meta-analysis. Parasit

Vectors. 2022 Jan 24;15(1):34.

22. Ibarra-Meneses AV, Chicharro C, Sánchez C, García E, Ortega S, Ndung'u JM,

et al. Loop-Mediated Isothermal Amplification Allows Rapid, Simple and

Accurate Molecular Diagnosis of Human Cutaneous and Visceral Leishmaniasis

Caused by *Leishmania infantum* When Compared to PCR. Microorganisms. 2021

Mar 16;9(3):610.

23. Kaminski MM, Abudayyeh OO, Gootenberg JS, Zhang F, Collins JJ. CRISPR-

based diagnostics. Nat Biomed Eng. 2021 Jul;5(7):643-656.

24. Chen JS, Ma E, Harrington LB, Da Costa M, Tian X, Palefsky JM, et al. CRISPR-

Cas12a target binding unleashes indiscriminate single-stranded DNase activity.

Science. 2018 Apr 27;360(6387):436-439.

25. Gootenberg JS, Abudayyeh OO, Lee JW, Essletzbichler P, Dy AJ, Joung J, et al.

Nucleic acid detection with CRISPR-Cas13a/C2c2. Science. 2017 Apr

28;356(6336):438-442.

26. Broughton JP, Deng X, Yu G, Fasching CL, Servellita V, Singh J, et al. CRISPR-

Cas12-based detection of SARS-CoV-2. Nat Biotechnol. 2020 Jul;38(7):870-874.

27. Wang X, Ji P, Fan H, Dang L, Wan W, Liu S, et al. CRISPR/Cas12a technology

combined with immunochromatographic strips for portable detection of African

swine fever virus. Commun Biol. 2020 Feb 11;3(1):62.

28. Li SY, Cheng QX, Wang JM, Li XY, Zhang ZL, Gao S, et al. CRISPR-Cas12a-

assisted nucleic acid detection. Cell Discov. 2018 Apr 24;4:20.

29. Cunningham CH, Hennelly CM, Lin JT, Ubalee R, Boyce RM, Mulogo EM, et

al. A novel CRISPR-based malaria diagnostic capable of *Plasmodium* detection,

species differentiation, and drug-resistance genotyping. EBioMedicine. 2021

Jun;68:103415.

30. Nguyen LT, Smith BM, Jain PK. Enhancement of trans-cleavage activity of

Cas12a with engineered crRNA enables amplified nucleic acid detection. Nat

Commun. 2020 Sep 30;11(1):4906.

31. Fozouni P, Son S, Díaz de León Derby M, Knott GJ, Gray CN, D'Ambrosio MV,

et al. Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and

mobile phone microscopy. Cell. 2021 Jan 21;184(2):323-333.e9.

32. Liu TY, Knott GJ, Smock DCJ, Desmarais JJ, Son S, Bhuiya A, et al. Accelerated

RNA detection using tandem CRISPR nucleases. Nat Chem Biol. 2021

Sep;17(9):982-988.

33. Nalefski EA, Patel N, Leung PJY, Islam Z, Kooistra RM, Parikh I, et al. Kinetic

analysis of Cas12a and Cas13a RNA-Guided nucleases for development of

improved CRISPR-Based diagnostics. iScience. 2021 Aug 18;24(9):102996.

34. Wang DG, Brewster JD, Paul M, Tomasula PM. Two methods for increased

specificity and sensitivity in loop-mediated isothermal amplification. Molecules.

2015 Apr 7;20(4):6048-59.

35. Joung J, Ladha A, Saito M, Kim NG, Woolley AE, Segel M, et al. Detection of

SARS-CoV-2 with SHERLOCK One-Pot Testing. N Engl J Med. 2020 Oct

8;383(15):1492-1494.

1032 36. Wang R, Qian C, Pang Y, Li M, Yang Y, Ma H, et al. opvCRISPR: One-pot visual

1033   RT-LAMP-CRISPR platform for SARS-cov-2 detection. Biosens Bioelectron.

1034   2021 Jan 15;172:112766.

1035 37. Sen A, Masetty M, Weerakoon S, Morris C, Yadav JS, Apewokin S, et al. Paper-

1036   based loop-mediated isothermal amplification and CRISPR integrated platform

1037   for on-site nucleic acid testing of pathogens. Biosens Bioelectron. 2024 Aug

1038   1;257:116292.

1039 38. Mukama O, Yuan T, He Z, Li Z, Habimana J de D, Hussain M, et al. A high

1040   fidelity CRISPR/Cas12a based lateral flow biosensor for the detection of HPV16

1041   and HPV18. Sensors and Actuators B: Chemical. 2020 Aug;316:128119. pii:

1042   S092540052030469X. doi: 10.1016/j.snb.2020.128119.

1043 39. Wang Y, Li J, Li S, Zhu X, Wang X, Huang J, et al. LAMP-CRISPR-Cas12-based

1044   diagnostic platform for detection of *Mycobacterium tuberculosis* complex using

1045   real-time fluorescence or lateral flow test. Mikrochim Acta. 2021 Sep

1046   20;188(10):347.

1047 40. Qiu X, Liu X, Ma X, Wang R, Chen S, Li F, et al. One-Pot Isothermal LAMP-

1048   CRISPR-Based Assay for *Klebsiella pneumoniae* Detection. Microbiol Spectr.

1049   2022 Aug 31;10(4):e0154522.

1050 41. Fang Y, Liu L, Zhao W, Dong L, He L, Liu Y, et al. Rapid and Sensitive Detection

1051   of *Verticillium dahliae* from Soil Using LAMP-CRISPR/Cas12a Technology. Int

1052   J Mol Sci. 2024 May 10;25(10):5185.

1053 42. Lee RA, Puig H, Nguyen PQ, Angenent-Mari NM, Donghia NM, McGee JP, et

1054   al. Ultrasensitive CRISPR-based diagnostic for field-applicable detection

1055   of *Plasmodium* species in symptomatic and asymptomatic malaria. Proc Natl

1056   Acad Sci U S A. 2020 Oct 13;117(41):25722-25731.

43. Wang X, Cheng M, Yang S, Xing C, Li Q, Zhu Y, et al. CRISPR/Cas12a

combined with RPA for detection of *T. gondii* in mouse whole blood. Parasit

Vectors. 2023 Jul 30;16(1):256.

44. Bengtson M, Bharadwaj M, Franch O, van der Torre J, Meerdink V, Schallig H,

et al. CRISPR-dCas9 based DNA detection scheme for diagnostics in resource-

limited settings. Nanoscale. 2022 Feb 3;14(5):1885-1895.

45. Dueñas E, Nakamoto JA, Cabrera-Sosa L, Huaihua P, Cruz M, Arévalo J, et al.

Novel CRISPR-based detection of *Leishmania* species. Front Microbiol. 2022 Sep

15;13:958693.

46. Wiggins TJ, Peng R, Bushnell RV, Tobin JK, MacLeod DA, Du K, et al.

Instrument-Free Point-of-Care Diagnostic for *Leishmania* Parasites. Diagnostics

(Basel). 2024 Dec 5;14(23):2744.

47. Yang K, Bi M, Mo X. CRISPR/Cas12a, combined with recombinase polymerase

amplification (RPA) reaction for visual detection of *Leishmania* species.

Microchem J. 2024 Dec;207:112283. doi: 10.1016/j.microc.2024.112283

48. Sima N, Dujeancourt-Henry A, Perlaza BL, Ungeheuer MN, Rotureau B, Glover

L. SHERLOCK4HAT: A CRISPR-based tool kit for diagnosis of Human African

Trypanosomiasis. EBioMedicine. 2022 Nov;85:104308.

49. Álvarez-Rodríguez A, Li Z, Jin BK, Stijlemans B, Geldhof P, Magez S. A

CRISPR-Cas-based recombinase polymerase amplification assay for ultra-

sensitive detection of active *Trypanosoma brucei evansi* infections. Front Mol

Biosci. 2025 Feb 14;12:1512970.

50. Ortiz-Rodríguez LA, Cabanzo R, Jaimes-Dueñez J, Mendez-Sanchez SC, Duque

JE. TropD-detector a CRISPR/LbCas12a-based system for rapid screening of

Trypanosoma cruzi in Chagas vectors and reservoirs. Sci Rep. 2025 May 31;15(1):19107.

51. Cherkaoui D, Mesquita SG, Huang D, Lugli EB, Webster BL, McKendry RA. CRISPR-assisted test for *Schistosoma haematobium*. Sci Rep. 2023 Mar 27;13(1):4990.

52. MacGregor SR, McManus DP, Sivakumaran H, Egwang TG, Adriko M, Cai P, et al. Development of CRISPR/Cas13a-based assays for the diagnosis of Schistosomiasis. EBioMedicine. 2023 Aug;94:104730.

53. Liu J, Wang X, Sheng F, Giri BR, Li S, Xia T, et al. Metagenomic sequencing for identifying pathogen-specific circulating DNAs and development of diagnostic methods for schistosomiasis. iScience. 2023 Jul 27;26(9):107495.

54. Parikesit AA, Hermantara R, Gregorius K, Siddharta E. Designing hybrid CRISPR-Cas12 and LAMP detection systems for treatment-resistant *Plasmodium falciparum* with in silico method. Narra J. 2023 Dec;3(3):e301.

55. Liang Y, Xie SC, Lv YH, He YH, Zheng XN, Cong W, et al. A novel single-tube LAMP-CRISPR/Cas12b method for rapid and visual detection of zoonotic *Toxoplasma gondii* in the environment. Infect Dis Poverty. 2024 Dec 10;13(1):94.

56. Guarnizo SAG, Basma L, Equilia S, Condori BJ, Malaga E, Defazio S, et al. A specific, stable, and accessible LAMP assay targeting the HSP70 gene of *Trypanosoma cruzi*. medRxiv [Preprint]. 2025 Jan 13:2025.01.12.25320185. doi: 10.1101/2025.01.12.25320185.

57. Kato H, Cáceres AG, Seki C, Silupu García CR, Holguín Mauricci C, Castro Martínez SC, et al. Further insight into the geographic distribution of *Leishmania* species in Peru by cytochrome b and mannose phosphate isomerase gene analyses. PLoS Negl Trop Dis. 2019 Jun 20;13(6):e0007496.

58. Sandoval-Juárez A, Minaya-Gómez G, Rojas-Palomino N, Cáceres O.

Identification of *Leishmania* species in patients derived to the National Institute

of Health, Peru. Rev Peru Med Exp Salud Publica. 2020 Jan-Mar;37(1):87-92.

59. Waterhouse AM, Procter JB, Martin DM, Clamp M, Barton GJ. Jalview Version

2--a multiple sequence alignment editor and analysis workbench. Bioinformatics.

2009 May 1;25(9):1189-91.

60. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, et al. Fast, scalable

generation of high-quality protein multiple sequence alignments using Clustal

Omega. Mol Syst Biol. 2011 Oct 11;7:539.

61. Alcántara R, Peñaranda K, Mendoza-Rojas G, Nakamoto JA, Martins-Luna J, Del

Valle-Mendoza J, et al. Unlocking SARS-CoV-2 detection in low- and middle-

income countries. Cell Rep Methods. 2021 Oct 21;1(7):100093.

62. Alcántara R, Peñaranda K, Mendoza-Rojas G, Nakamoto JA, Dueñas E, Alvarez

D, et al. UnCovid: A versatile, low-cost, and open-source protocol for SARS-

CoV-2 RNA detection. STAR Protoc. 2021 Dec 17;2(4):100878.

63. Mendoza-Rojas G, Sarabia-Vega V, Sanchez-Castro A, Tello L, Cabrera-Sosa L,

Nakamoto JA, et al. A low-cost and open-source protocol to produce key enzymes

for molecular detection assays. STAR Protoc. 2021 Nov 1;2(4):100899.

64. Jara M, Adaui V, Valencia BM, Martinez D, Alba M, Castrillon C, et al. Real-

time PCR assay for detection and quantification of *Leishmania* (*Viannia*)

organisms in skin and mucosal lesions: exploratory study of parasite load and

clinical parameters. J Clin Microbiol. 2013 Jun;51(6):1826-33.

65. Yuan CC, Miley W, Waters D. A quantification of human cells using an ERV-3

real time PCR assay. J Virol Methods. 2001 Feb;91(2):109-17.

66. MedCalc Software Ltd. Diagnostic test evaluation calculator. Available from:
https://www.medcalc.org/calc/diagnostic_test.php (Version 23.0.1; accessed
August 21, 2024)

67. Parida M, Sannarangaiah S, Dash PK, Rao PV, Morita K. Loop mediated
isothermal amplification (LAMP): a new generation of innovative gene
amplification technique; perspectives in clinical diagnosis of infectious diseases.
Rev Med Virol. 2008 Nov-Dec;18(6):407-21.

68. Lopez M, Inga R, Cangalaya M, Echevarria J, Llanos-Cuentas A, Orrego C, et al.
Diagnosis of *Leishmania* using the polymerase chain reaction: a simplified
procedure for field work. Am J Trop Med Hyg. 1993 Sep;49(3):348-56.

69. World Health Organization. Ending the neglect to attain the sustainable
development goals: a road map for neglected tropical diseases 2021–2030. World
Health   Organization.   2020.   Available   from:
https://iris.who.int/handle/10665/338565.

70. Gow I, Smith NC, Stark D, Ellis J. Laboratory diagnostics for human *Leishmania*
infections: a polymerase chain reaction-focussed review of detection and
identification methods. Parasit Vectors. 2022 Nov 5;15(1):412.

71. Gow I, Smith N, Stark D, Ellis J. Molecular Detection of Neglected Tropical
Diseases: The Case for Automated Near-Point-of-Care Diagnosis of
Leishmaniasis. Am J Trop Med Hyg. 2022 Nov 30;108(1):2-6.

72. Deborggraeve S, Laurent T, Espinosa D, Van der Auwera G, Mbuchi M, Wasunna
M, et al. A simplified and standardized polymerase chain reaction format for the
diagnosis of leishmaniasis. J Infect Dis. 2008 Nov 15;198(10):1565-72.

73. Carson C, Quinnell RJ, Holden J, Garcez LM, Deborggraeve S, Courtenay O.
Comparison of *Leishmania* OligoC-TesT PCR with conventional and real-time

PCR for Diagnosis of canine *Leishmania* infection. J Clin Microbiol. 2010 Sep;48(9):3325-30.

74. van Dijk NJ, Hagos DG, Huggins DM, Carrillo E, Ajala S, Chicharro C, et al. Simplified molecular diagnosis of visceral leishmaniasis: Laboratory evaluation of miniature direct-on-blood PCR nucleic acid lateral flow immunoassay. PLoS Negl Trop Dis. 2024 May 7;18(5):e0011637.

75. Dixit KK, Verma S, Singh OP, Singh D, Singh AP, Gupta R, et al. Validation of SYBR green I based closed tube loop mediated isothermal amplification (LAMP) assay and simplified direct-blood-lysis (DBL)-LAMP assay for diagnosis of visceral leishmaniasis (VL). PLoS Negl Trop Dis. 2018 Nov 15;12(11):e0006922.

76. Ibarra-Meneses AV, Cruz I, Chicharro C, Sánchez C, Biéler S, Broger T, et al. Evaluation of fluorimetry and direct visualization to interpret results of a loop-mediated isothermal amplification kit to detect *Leishmania* DNA. Parasit Vectors. 2018 Apr 17;11(1):250.

77. Puri M, Brar HK, Mittal N, Madan E, Srinivasan R, Rawat K, et al. Rapid diagnosis of *Leishmania* infection with a portable loopmediated isothermal amplification device. J Biosci. 2021;46(4):92.

78. Travi BL, De los Santos MB, Shelite TR, Santos RP, Rosales LA, Castellanos-Gonzalez A, et al. Diagnostic Efficacy of Recombinase-Polymerase-Amplification Coupled with Lateral Flow Strip Reading in Patients with Cutaneous Leishmaniasis from the Amazonas Rainforest of Perú. Vector Borne Zoonotic Dis. 2021 Dec;21(12):941-947.

79. Kobialka RM, Ceruti A, Roy M, Roy S, Chowdhury R, Ghosh P, et al. Portable smartphone-based molecular test for rapid detection of *Leishmania* spp. Infection. 2024 Aug;52(4):1315-1324.

80. Qian X, Xu Q, Lyon CJ, Hu TY. CRISPR for companion diagnostics in low-
resource settings. Lab Chip. 2024 Oct 9;24(20):4717-4740.

81. Martínez DY, Verdonck K, Kaye PM, Adaui V, Polman K, Llanos-Cuentas A, et
al. Tegumentary leishmaniasis and coinfections other than HIV. PLoS Negl Trop
Dis. 2018 Mar 1;12(3):e0006125.

82. Leon W, Fouts DL, Manning J. Sequence arrangement of the 16S and 26S rRNA
genes in the pathogenic haemoflagellate *Leishmania donovani*. Nucleic Acids
Res. 1978 Feb;5(2):491-504.

83. Inga R, De Doncker S, Gomez J, Lopez M, Garcia R, Le Ray D, et al. Relation
between variation in copy number of ribosomal RNA encoding genes and size of
harbouring chromosomes in *Leishmania* of subgenus *Viannia*. Mol Biochem
Parasitol. 1998 May 1;92(2):219-28.

84. Simpson L. The mitochondrial genome of kinetoplastid protozoa: genomic
organization, transcription, replication, and evolution. Annu Rev Microbiol.
1987;41:363-82.

85. Takagi H, Itoh M, Islam MZ, Razzaque A, Ekram AR, Hashighuchi Y, et al.
Sensitive, specific, and rapid detection of *Leishmania donovani* DNA by loop-
mediated isothermal amplification. Am J Trop Med Hyg. 2009 Oct;81(4):578-82.

86. Verma S, Avishek K, Sharma V, Negi NS, Ramesh V, Salotra P. Application of
loop-mediated isothermal amplification assay for the sensitive and rapid diagnosis
of visceral leishmaniasis and post-kala-azar dermal leishmaniasis. Diagn
Microbiol Infect Dis. 2013 Apr;75(4):390-5.

87. Celeste JLL, Caldeira RL, Pires SDF, Silveira KD, Soares RP, de Andrade HM.
Development and evaluation of a loop-mediated isothermal amplification assay

for rapid detection of *Leishmania amazonensis* in skin samples. Exp Parasitol. 2019 Aug;203:23-29.

88. Adams ER, Schoone GJ, Ageed AF, Safi SE, Schallig HD. Development of a reverse transcriptase loop-mediated isothermal amplification (LAMP) assay for the sensitive detection of *Leishmania* parasites in clinical samples. Am J Trop Med Hyg. 2010 Apr;82(4):591-6.

89. Nzelu CO, Gomez EA, Cáceres AG, Sakurai T, Martini-Robles L, Uezato H, et al. Development of a loop-mediated isothermal amplification method for rapid mass-screening of sand flies for *Leishmania* infection. Acta Trop. 2014 Apr;132:1-6.

90. Nzelu CO, Cáceres AG, Guerrero-Quincho S, Tineo-Villafuerte E, Rodriquez-Delfin L, Mimori T, et al. A rapid molecular diagnosis of cutaneous leishmaniasis by colorimetric malachite green-loop-mediated isothermal amplification (LAMP) combined with an FTA card as a direct sampling tool. Acta Trop. 2016 Jan;153:116-9.

91. Abbasi I, Kirstein OD, Hailu A, Warburg A. Optimization of loop-mediated isothermal amplification (LAMP) assays for the detection of *Leishmania* DNA in human blood samples. Acta Trop. 2016 Oct;162:20-26.

92. Chaouch M, Mhadhbi M, Adams ER, Schoone GJ, Limam S, Gharbi Z, et al. Development and evaluation of a loop-mediated isothermal amplification assay for rapid detection of *Leishmania infantum* in canine leishmaniasis based on cysteine protease B genes. Vet Parasitol. 2013 Nov 15;198(1-2):78-84.

93. Ruang-Areerate T, Sukphattanaudomchoke C, Thita T, Leelayoova S, Piyaraj P, Mungthin M, et al. Development of loop-mediated isothermal amplification

(LAMP) assay using SYBR safe and gold-nanoparticle probe for detection of *Leishmania* in HIV patients. Sci Rep. 2021 Jun 9;11(1):12152.

94. Adams ER, Schoone G, Versteeg I, Gomez MA, Diro E, Mori Y, et al. Development and Evaluation of a Novel Loop-Mediated Isothermal Amplification Assay for Diagnosis of Cutaneous and Visceral Leishmaniasis. J Clin Microbiol. 2018 Jun 25;56(7):e00386-18.

95. Mukhtar M, Ali SS, Boshara SA, Albertini A, Monnerat S, Bessell P, et al. Sensitive and less invasive confirmatory diagnosis of visceral leishmaniasis in Sudan using loop-mediated isothermal amplification (LAMP). PLoS Negl Trop Dis. 2018 Feb 14;12(2):e0006264.

96. Hossain F, Picado A, Owen SI, Ghosh P, Chowdhury R, Maruf S, et al. Evaluation of Loopamp™ *Leishmania* Detection Kit and *Leishmania* Antigen ELISA for Post-Elimination Detection and Management of Visceral Leishmaniasis in Bangladesh. Front Cell Infect Microbiol. 2021 Apr 26;11:670759.

97. Vink MMT, Nahzat SM, Rahimi H, Buhler C, Ahmadi BA, Nader M, et al. Evaluation of point-of-care tests for cutaneous leishmaniasis diagnosis in Kabul, Afghanistan. EBioMedicine. 2018 Nov;37:453-460.

98. Schallig HDFH, Hu RVP, Kent AD, van Loenen M, Menting S, Picado A, et al. Evaluation of point of care tests for the diagnosis of cutaneous leishmaniasis in Suriname. BMC Infect Dis. 2019 Jan 7;19(1):25.

99. Ghosh P, Chowdhury R, Maruf S, Picado A, Hossain F, Owen SI, et al. Gauging the skin resident *Leishmania* parasites through a loop mediated isothermal amplification (LAMP) assay in post-kala-azar dermal leishmaniasis. Sci Rep. 2022 Oct 27;12(1):18069.

100.   Taye B, Melkamu R, Tajebe F, Ibarra-Meneses AV, Adane D, Atnafu S,

et al. Evaluation of Loopamp *Leishmania* detection kit for the diagnosis of

cutaneous leishmaniasis in Ethiopia. Parasit Vectors. 2024 Oct 15;17(1):431.

101.   Peng R, Yuqing F, Wiggins TJ, Bahadori N, Rogers JS, Waitkus J, et al.

Multiple-Channel Funnel Adapted Sensing Tube (MFAST) for the Simple and

Duplex Detection of Parasites. ACS Sens. 2025 Apr 25;10(4):2678-2688.

102.   Mabey D, Peeling RW, Ustianowski A, Perkins MD. Diagnostics for the

developing world. Nat Rev Microbiol. 2004 Mar;2(3):231-40.

103.   Land KJ, Boeras DI, Chen XS, Ramsay AR, Peeling RW. REASSURED

diagnostics to inform disease control strategies, strengthen health systems and

improve patient outcomes. Nat Microbiol. 2019 Jan;4(1):46-54.

104.   Dineva MA, MahiLum-Tapay L, Lee H. Sample preparation: a challenge

in the development of point-of-care nucleic acid-based assays for resource-limited

settings. Analyst. 2007 Dec;132(12):1193-9.

105.   Gunaratna G, Manamperi A, Böhlken-Fascher S, Wickremasinge R,

Gunawardena K, Yapa B, et al. Evaluation of rapid extraction and isothermal

amplification techniques for the detection of *Leishmania donovani* DNA from

skin lesions of suspected cases at the point of need in Sri Lanka. Parasit Vectors.

2018 Dec 22;11(1):665.

106.   Nguyen LT, Rananaware SR, Pizzano BLM, Stone BT, Jain PK. Clinical

validation of engineered CRISPR/Cas12a for rapid SARS-CoV-2 detection.

Commun Med (Lond). 2022 Jan 12;2:7.

107.   Mondal D, Ghosh P, Khan MA, Hossain F, Böhlken-Fascher S,

Matlashewski G, et al. Mobile suitcase laboratory for rapid detection of

Leishmania donovani using recombinase polymerase amplification assay. Parasit

Vectors. 2016 May 13;9(1):281.

108.   Ghosh P, Sharma A, Bhattarai NR, Abhishek K, Nisansala T, Kumar A, et

al. A Multi-Country, Single-Blinded, Phase 2 Study to Evaluate a Point-of-Need

System for Rapid Detection of Leishmaniasis and Its Implementation in Endemic

Settings. Microorganisms. 2021 Mar 12;9(3):588.

109.   Milenia Biotec GmbH. A short guide for improved readout performance.

Available from: https://www.milenia-biotec.com/uploads/2019/07/improved-

CRISPR-readout_final-1.pdf

1285

Supporting information captions

S1 Fig. Multiple sequence alignment of representative kDNA minicircle sequences

from members of the *L.* (*Viannia*) and *L.* (*Leishmania*) subgenera, with LAMP

primer binding regions and crRNA target site highlighted. A total of 24 *L.* (*Viannia*)

and 35 *L.* (*Leishmania*) sequences were aligned using Clustal Omega (alignments were

performed separately for each subgenus) and visualized in Jalview v2.11.4.1. The

locations of primer binding regions as well as of the crRNA target site and PAM sequence

in the target DNA are highlighted with colors to indicate sequence conservation within

the *L.* (*Viannia*) subgenus and sequence divergence within the *L.* (*Leishmania*) subgenus.

Nucleotide variants are represented by spaces in the alignment. The kDNA minicircle

sequence from the *L.* (*V.*) *braziliensis* M2904 strain (GenBank accession no.

KY698803.1) exhibited 100% identity across all primer and crRNA target regions. The

sequences shown are from selected representative strains/isolates of a given *Leishmania*

species; additional species and sequences can be examined in the full alignments included

in the S1 File. Figure created with BioRender.com.

S2 Fig. Multiple sequence alignment of representative 18S rDNA sequences from members of the *Leishmania* and *Trypanosoma* genera, with LAMP primer binding regions and crRNA target site highlighted. A total of 31 sequences (16 from *Leishmania* spp. and 15 from *Trypanosoma* spp.) were aligned using Clustal Omega and visualized in Jalview v2.11.4.1. Primer binding regions as well as the crRNA target site and PAM sequence in the target DNA are highlighted with colors to indicate sequence conservation within the *Leishmania* genus and sequence variations within the *Trypanosoma* genus. Nucleotide variants are represented by spaces in the alignment. The sequences shown are from selected representative strains/isolates of a given species; additional species and sequences can be examined in the full alignments included in the S2 File. Figure created with BioRender.com.

S3 Fig. Optimization of the incubation time of the LAMP reaction. To determine the minimum necessary incubation time of the LAMP reaction for consistent DNA amplification, tests were performed at different reaction times for *Leishmania* kDNA (10, 20, 30, and 40 min) and 18S rDNA (10, 30, 40, 50, and 60 min) targets. The number and text enclosed in a rectangle indicates the LAMP reaction time. The amplification efficiency was assessed using varying amounts of template DNA (*L. braziliensis* M2904 gDNA), corresponding to approximately 2×10^2, 2×10^{-1}, and 2×10^{-3} genome equivalents. A negative control (NTC) reaction was tested in parallel. Raw fluorescence signals from Cas12a reactions are shown for kDNA (A-D) and 18S rDNA (G-K) for one representative technical replicate. Normalized data (fluorescence ratio at $t = 25$ min) from two technical replicates are shown in panels E (kDNA) and L (18S rDNA). A fluorescence ratio ≥ 2 is considered detected. Fluorescence measurements in this figure were taken on the Varioskan LUX plate reader. LAMP reaction products (5 µL each) of kDNA (F) and 18S rDNA (M) were analyzed by 2% agarose gel electrophoresis ran at

100 V for 1 h using SYBR Gold staining. L, 100 bp DNA ladder (ABclonal). Since space

was tight on the agarose gel images, we had to abbreviate the labels for each lane. For

instance, "10^2" actually represents "2×10^2" as indicated in other panels of this figure.

S4 Fig. Optimization of CRISPR-based detection assays using a lateral flow readout.

(A) Design of the Milenia GenLine HybriDetect test strips and readout interpretation.

(Left) In the absence of the specific genetic target, the intact biotin-FAM labeled reporter

molecule flows to the control line (C-line). This is interpreted as a negative test result.

(Right) Upon recognition of the genetic target, the CRISPR RNP complex cleaves the

reporter molecule, which flows to the test line (T-line). The signal intensity of the C-line

is weakened. If cleavage of the reporter molecule is partial, both the C-line and T-line

may appear with comparable intensity. Both scenarios are interpreted as a positive test

result. Figure adapted from [109] and created with BioRender.com. (B-F) Different

parameters influencing the LFA readout performance were evaluated to achieve

consistent results: reporter concentration (B), assay buffer (C), incubation temperature

(D) and reaction time (E) of the Cas12a assay, and the concentration of PEG-8000 (F).

Results shown here correspond to the kDNA LAMP-CRISPR assay.

S5 Fig. Workflow from sample preparation to LAMP-CRISPR assays for analytical

specificity testing. Figure created with BioRender.com.

S6 Fig. Results of LAMP-CRISPR detection with fluorescence readout in a group of

clinical samples. Raw fluorescence curves generated by Cas12a detection of LAMP

amplicons from *Leishmania* kDNA (A) and 18S rDNA (B) targets in a representative

group of clinical samples harboring varying parasite load levels (see S1 Dataset) and ran

in the same assay plate per genomic target. Out of the 8 tested samples shown, 6 showed

robust fluorescence curves indicating the presence of *Leishmania* kDNA molecules

(panel A; samples coded S16, S23, S31, S52, S72, and S75) whereas the 18S rDNA target

was detected in 4 of them (panel B; samples coded S16, S23, S52, and S75). Fluorescence

measurements in this figure were taken on the Synergy H1 plate reader. The respective

LAMP amplicons (5 µL) targeting kDNA (C) or 18S rDNA (D) were analyzed by 2%

agarose gel electrophoresis (100 V, 60 min) using SYBR Gold staining. Controls included

a positive control (PC, 5×10^4 genome equivalents from *L. braziliensis* M2904 gDNA),

a human negative control (HC, human PBMC gDNA), and a no-template control (NTC)

of the LAMP reaction.

S7 Fig. Results of LAMP-CRISPR detection with LFA readout in a group of clinical

samples. Clinical samples chosen for this pilot testing (n = 8) were categorized according

to the parasite load levels and tested with kDNA and 18S LAMP-CRISPR assays. Lateral

flow testing was performed on two assay repeats, R1 and R2, per sample. Visualization

on the lateral flow strips (Milenia GenLine HybriDetect strips) was achieved through the

cleavage of the biotin-FAM reporter molecule. Following LFA analysis, the strips were

placed into the cassette housing for image acquisition. C, control line; T, test line.

Controls included DNA samples from two non-leishmaniasis patients (i.e., kDNA qPCR-

negative; samples 09 and C7), a positive control (PC, 2×10^2 genome equivalents from

L. braziliensis M2904 gDNA), a human negative control (HC, 20 ng of human PBMC

gDNA), and a no-template control (NTC) of the LAMP reaction.

S1 Table. Primer and crRNA template sequences used in this study.

S1 File. *In silico* alignment of *Leishmania* kDNA minicircle sequences from *Viannia*

and *Leishmania* subgenera, and location of primer and crRNA binding sites. This

file contains sequence alignments and visualizations used to assess the *in silico* specificity

of the designed LAMP primers and Cas12a crRNA within conserved regions of

Leishmania kDNA minicircles. A total of 1,060 aligned sequences from strains/isolates

belonging to the *L.* (*Viannia*) subgenus and 965 aligned sequences from strains/isolates

of the *L.* (*Leishmania*) subgenus were included. Primer and crRNA binding regions were manually annotated using Jalview v2.11.4.1 to enhance visualization and facilitate identification of conserved target sites. Additionally, a subset of representative sequences, 24 *L.* (*Viannia*) and 35 *L.* (*Leishmania*), is provided in separate alignment project files to illustrate kDNA minicircle sequence conservation and divergence across the two subgenera (see also S1 Fig).

S2 File. *In silico* alignment of 18S rDNA sequences from *Leishmania* and *Trypanosoma* genera, and location of primer and crRNA binding sites. This file contains the alignments and visualizations used to evaluate the *in silico* specificity of the designed LAMP primers and Cas12a crRNA targeting the 18S rDNA. It includes 37 aligned sequences of *Leishmania* spp. and 272 of *Trypanosoma* spp. Primer and crRNA binding regions were manually annotated using Jalview v2.11.4.1 to enhance visualization and identification. Additionally, an alignment of a subset of 31 representative sequences (16 *Leishmania*, 15 *Trypanosoma*) is provided for visualization of 18S rDNA sequence conservation and divergence across the two genera (see also S2 Fig).

S1 Dataset. Excel file containing the data on tested clinical samples generated during the current study. This file contains the LAMP-CRISPR and qPCR data on tested clinical samples, as well as the determination of threshold cutoff values for fluorescence-based CRISPR-Cas12a assay result interpretation.

Author Contributions

Conceptualization: Vanessa Adaui.

Formal analysis: Eva Dueñas, Percy Huaihua, Vanessa Adaui.

Funding acquisition: Vanessa Adaui.

Investigation: Eva Dueñas, Ingrid Tirado, Percy Huaihua, Ariana Parra del Riego, Luis

Cabrera-Sosa, Jose A. Nakamoto, Carlos M. Restrepo.

Project administration: Vanessa Adaui.

Resources: Luis Cabrera-Sosa, Jose A. Nakamoto, María Cruz, Carlos M. Restrepo, Jorge

Arévalo, Vanessa Adaui.

Supervision: Vanessa Adaui, Jorge Arévalo.

Visualization: Eva Dueñas, Ingrid Tirado.

Writing – original draft: Eva Dueñas, Ariana Parra del Riego, Vanessa Adaui.

Writing – review & editing: Eva Dueñas, Ingrid Tirado, Percy Huaihua, Ariana Parra del

Riego, Luis Cabrera-Sosa, Jose A. Nakamoto, María Cruz, Carlos M. Restrepo, Jorge

Arévalo, Vanessa Adaui.

1412

Acknowledgments

We thank Pohl Milón (Universidad Peruana de Ciencias Aplicadas) for inspiring

discussions; Yomara Romero (Universidad Peruana de Ciencias Aplicadas) for assistance

with sequence alignments and advice on their presentation; Edith Málaga and Manuela

Verástegui (Universidad Peruana Cayetano Heredia) for providing genomic DNA from

the *Trypanosoma cruzi* strains tested here; and the Office of Research at the Universidad

Peruana de Ciencias Aplicadas for the support provided to carry out this research work.

1420

Funding Statement

1422 This work was supported by ProCiencia, the Peruvian National Council for Science,

1423 Technology, and Technological Innovation (CONCYTEC) - The World Bank (contract

1424 036-2019-FONDECYT-BM-INC.INV) and by the Universidad Peruana de Ciencias

1425 Aplicadas (internal fund C-005-2024). I.T. was supported by a postgraduate scholarship

1428

1429

Figure

DNA target

Forward and backward external primers: F3 B3

Forward and backward internal primers:
FIP: F1c — F2
BIP: B1c — B2

Forward and backward loop primers: LF LB

crRNA target sequence: — Kinetoplast (kDNA) minicircles — 18S rDNA   PAM sequence: 5' VAAA 3'

18S crRNA target sequence:
5' TGACTCAATTCATTCCGTGCGAAA 3'

kDNA-crRNA target sequence:
5' TGGCATACAGAAACCCCGTTCAAA 3'

Figure

Figure

A

kDNA   18S rDNA

L.(V.)braziliensis M2904
L.(V.)braziliensis M2903
L.(V.)braziliensis LC2177
L.(V.)braziliensis LC2043
L.(V.)peruviana WR-2771
L.(V.)peruviana HB86
L.(V.)peruviana LCA08
L.(V.)guyanensis M4147
L.(V.)lainsoni M6426
L.(V.)panamensis BD-02
L.(L.)amazonensis M2269
L.(L.)mexicana BEL21
L.(L.)aristidesi GML
L.(L.)major WR-1088
L.(L.)donovani WR-2801
L.(L.)infantum P142
T.cruzi Tulahuen
T.cruzi VT-1
T.cruzi Sylvio X10
M.tuberculosis PA155-18C
P.falciparum HB3
Human control

2   3   2   3

B

Human control   NTC   Lbra M2904   Lguy M4147   Lper LCA08   Mt PA155-18C   Pf HB3   Tc Tulahuen   Tc Sylvio X10   Tc VT-1

1   2   3   4   5   6   7   8   9   10

— T

— C

— T

— C

Negative
controls

Positive
controls

Non-related
microbes

T. cruzi
strains

Figure

Figure

Figure

Figure

Figure